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Abstract
Safety is an important aspect in the licensing of any vaccine. Prior to placement on the 
market, any risks and side-effects attributable to the vaccine must be as well documented as 
possible. One of the main priorities in the safety of a vaccine containing live micro­
organisms is the level of neurovirulent activity of the vaccine components.
Every batch of the oral polio vaccine is tested for neurovirulent activity by inoculation into 
the central nervous system of macaques. Seed stocks for the live mumps virus vaccines are 
tested likewise. However, relying on the macaque model is an inadequate marker of 
neurovirulence of mumps vaccines as the animal system does not fully mimic the human 
pathological processes, thereby making results difficult to interpret.
Further inadequacies of this model include the small experimental group used, the cost of 
purchasing and maintaining macaques, as well as the ethics involved in using non-human 
primates. As a result, many alternative animal models have been investigated, from using 
different monkey species to using smaller animals. Of the animal models investigated, the 
marmoset monkey model shows prospects; however, the use of large animals is not 
desirable. Of the smaller animal models, the rat model, currently being developed by the 
Food and Drug Administration in USA and NIBSC, holds many advantages. Rats are cheaper, 
easier to handle and can be used in larger experimental groups, and the CNS of neonatal 
rats shows recordable and reproducible susceptibility to the mumps virus. The aim of this 
project was to evaluate the rat model using various vaccine, vaccine-derived and wild-type 
viruses. These were used in order to establish if the model can distinguish between virulent 
wild-type and attenuated vaccine strains and mixed and pure preparations of vaccines of a 
related strain shown to have caused meningitis in children.
The results conclude that the neo-natal rat model is on a par with the macaque model in 
distinguishing between wild-type and vaccine strains; however, neither model can 
distinguish between a vaccine and its derived variants causing adverse events in the 
recipients. However, a smaller animal model is more desirable and the method of diagnosing
neurovirulent activity in rats, by measuring the enlargement of the lateral ventricle, is much 
simpler than histological analysis of lesions in the macaque brain. The results of the 
FDA/NIBSC collaboration showed varying degrees of difference, highlighting a need to 
standardize the test for future applications.
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1 Introduction
1.1 General Introduction
A popular misconception concerning the mumps virus (MuV) is that it is the causative agent 
of nothing more than a trivial childhood illness. This concept may have arisen due to the age 
and familiarity of the disease. The first known documentation of mumps disease was in the 
5^  ^Century B.C by Hippocrates, who described a mild epidemic illness characterised by a 
non-suppurative swelling near the ears; this is clinically referred to as parotitis. In 1935, 
Johnson and Goodpasture confirmed a virus as the aetiological agent of the mumps disease. 
Further experimentation, using Johnson's neighbour's children, allowed them to define the 
incubation period of the virus close to 18 days. Johnson and Goodpasture continued their 
research and successfully isolated and propagated the virus in embryonated hens eggs.
MuV transmission is via droplet spread and it can infect the nasal mucosa or upper 
respiratory mucosal epithelium. This results in viremia and the virus disseminates to most 
organ systems, including the central nervous system (CNS) (Rubin et al 1998).
Complications arising from viral dissemination include the invasion of visceral organs; 
epididymo-orchitis, meningo-encephalitis, acute or chronic encephalitis, pancreatitis, 
oophoritis, mastitis, myocarditis and spontaneous abortion (WHO Review 1994). The most 
serious complications occur in the post-pubescent population.
The mumps disease and its associated complications declined after the introduction of an 
attenuated mumps virus vaccine. The vaccine is a result of serial passaging of a live mumps 
virus in embryonated hens eggs. The mumps vaccine can be administered in a variety of 
forms, as a monovalent mumps vaccine, a bivalent measles and mumps vaccine, MM, or a 
trivalent MMR vaccine, a combined vaccine incorporating live attenuated measles and rubella 
in conjunction with mumps. The rubella virus is known to cause congenital rubella syndrome 
(CRS), which can lead to foetal defects if the virus infects a pregnant woman. The measles 
virus (MV) can indirectly cause immune suppression although the virus infection is self-
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limiting. For the ease of administrating the three attenuated vaccine viruses they are 
combined together to generate a single vaccine preparation. The MMR vaccine was 
introduced into the UK immunisation schedule in 1988 and has been used successfully ever 
since to help maintain a protective population immunity.
As effective as the vaccines have proven to be, they remain restricted to more affluent 
countries due to logistic and economic reasons.
1.2 The Mumps Virus
1.2.1 Classification
MuV is a member of the super-family Mononegavirales, which contains the single-stranded 
non-segmented negative sense RNA viruses. Single-stranded RNA viruses are classified as 
being either positive or negative sense. The encapsidated molecule of a positive sense RNA 
virus is infectious by itself and corresponds to functional messenger RNA (mRNA). Negative 
sense viruses are complementary to the mRNA produced from them and are strictly 
dependent on viral transcriptase enzymes packaged within the virions to initiate the 
infectious cycle (Baltimore et al 1971). Members of the super-family Mononegavirales are 
non-segmented and comprise four families Bornaviridae, Rhabdoviridae, Paramyxoviridae 
and Fiioviridae (Pringle and Easton, 1997). In this superfamily, there are not only those 
human and animal pathogens that have been recognised since early studies in virology, but 
also newly emerging agents, such as Nipah virus and Hendra virus.
Originally, MuV was classified in the MyxoviridaefaroWy alongside the influenza virus. This 
was primarily due to its ability to agglutinate red blood cells. Currently MuV is classified in 
the Rubuiavirus qer\us of the Paraxmyxoviridae famVj (Rima et al 1995).
The name paramyxo is derived from the Greek para meaning 'close to' (in reference to the 
families close relationship) and myxa meaning mucus (in reference to the site of infection).
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Table 1.1 shows the present classification of the Mononegavirales ar\6 lists representative 
species from each genus. This classification system is based on the morphological 
characteristics, genome organisation and sequence relationships of the viruses.
Table 1.1: Representative virus species in the super family Mononegavirales
Family/SubFamily Genus Species
Paramyxoviridae
Paramyxovirinae Respirovirus Sendai Virus 
Human Parainfluenza 1 
Human Parainfluenza 3
Morbiiiivirus Measles Virus 
Rinderpest Virus 
Canine Distemper Virus 
Phocine Distemper Virus 
Hendra Virus
Rubuiavirus Newcastle Disease Virus 
Simian Virus 5 
Mumps Virus
Pneumovirinae Pneumovirus Human Respiratory Syncytial Virus 
Bovine Respiratory Syncytial Virus
Rhabdoviridae Vesiculovirus 
Lyssa virus 
Ephemerovirus 
Cytohabdovirus 
Nucieohabdovirus
Vesicular Stomatitis Virus 
Rabies Virus
Bovine ephemeral fever virus 
Lettuce necrotic yellow virus 
Potato yellow dwarf virus
Fiioviridae Fiiovirus Marburg Virus 
Ebola Virus
Bornaviridae Bornavirus Borna Disease Virus
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1.2.2 Biological Characteristics
Mumps is an enveloped virion of approximately ISOnm in diameter and is pleomorphic in 
shape. The virion contains the non-segmented negative-sense RNA in association with three 
viral proteins, the nucleocapsid protein (NP), polymerase protein (P) and the large protein 
(L). This nucleocapsid complex is also found associated with the membrane bound matrix 
protein (M). There are two surface glycoproteins embedded in the lipid bilayer known as the 
haemagglutinin-neuraminidase (HN) glycoprotein and the fusion (F) glycoprotein. The small- 
hydrophobic (SH) protein which is possessed by a few rubulaviruses, including mumps and 
simian virus 5 (SV5), is thought to be membrane associated. Though its actual function is 
unknown, it has been postulated to be involved in apoptosis in SV5 (He et al, 2001). As with 
other enveloped RNA viruses, such as the human immunodeficiency virus (HIV) and MV, the 
budding virion envelopes itself in the host plasma membrane and buds in to the extracellular 
medium adopting the membrane as its own. Figure 1.1 is a structural representation of the 
mumps virus.
1.2.3 Genomic Structure
The average MuV genome is approximately 15,384 nucleotides in length and encodes 
information for seven genes in the following order:
3' -  NP -  P/V -  M -  F -  SH -  HN -  L -  5'
A fifty-five nucleotide non-coding region located at the 3' terminus is called the leader 
sequence and a twenty-four nucleotide non-coding region located at the 5' terminus is called 
the trailer sequence. The length of the genes and the protein products produced by them 
are shown in table 1.2. Transcription of the P gene gives rise to more than one translatable 
mRNA species, due to overlapping reading frames (ORF). These allow the virus to maximise 
its production of different proteins whilst minimising its genome length. The precise function 
of the V protein is unknown at present.
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HN G1 geo protein
G1 gcoprotein 
L Protein
- M M protein
NP Protein
RNA Genome
P Protein
Figure 1.1: The structural representation of MuV.
Showing six of the proteins of MuV including the RNA genome. The SH protein has not 
been localised within the MuV and its precise function is unknown.
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Table 1.2: Length of mumps virus genes and number of deduced amino acids (Elango 
et al 1989).
Gene Nucleotide
Length
Amino Acid 
Length
Expected 
Molecular 
Weight fKd)
NP 1,845 549 69
P 1,312 391 45
M 1,253 375 40
F 1,721 538 65
SH 310 57 6.7
HN 1,887 582 80
L 6,925 2261 180
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1.3 Viral Proteins
1.3.1 The Nucleocapsid (NP) Protein.
The NP protein associates with the P and L proteins to form a nucleocapsid complex; a 
single-stranded, left handed helical structure of about 1pm in length which interacts with the 
RNA to form a ribonucleoprotein (RNP). The RNP complex is a flexible structure coiled within 
the virus particle and its function is thought to be the protection of genomic RNA from 
degradation. The RNA and the L and P proteins associate with the NP protein during 
transcription and replication; the intracellular concentration of unassembled NP controls this 
association and therefore, transcription and replication processes are indigenously self 
regulated.
The gene sequence of the NP protein has been described for many paramyxoviruses 
(Morgan et al 1984, Rozenblat et al 1985, Ishida et al 1986 and Elango et al 1989). The 
results of these studies conclude that the NP protein consists of two domains corresponding 
to its N and C termini. The N-terminus is a globular domain with an overall positive charge 
that increases the NP protein's affinity for RNA binding and subsequently, RNA protection. 
The N-terminus is highly conserved amongst paramyxoviruses within the genus members 
(Liston et al 1997). NP-NP protein binding is also possible via the N-terminus and is essential 
for RNP formation (Liston et al 1997).
The C-terminus is not as well conserved among paramyxoviruses as the N-terminal region, 
and contains the protein phosphorylation and antigenic sites (Hsu and Kingsbury 1982). The 
C-terminus has also been shown to be responsible for mediating the binding of the P protein 
to nucleocapsids (Ryan and Porter 1990). By cleaving and removing the C-terminus from the 
NP protein, Heggeness et al (1981) showed that the C-terminus is not essential for RNA 
binding or protection.
1.3.2 The Polymerase (P) Protein.
The highly phosphorylated P protein is located within cytoplasmic inclusions. Its main 
function is to associate with the L protein to form the viral polymerase P-L and direct RNA
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synthesis in the cytoplasm. The P-L polymerase complex also associates with unassembled 
NP protein to form the active complex of RNA encapsidation (Horikami et al 1992). The 
length of the P gene has been shown to be variable amongst paramyxoviruses and also 
within the rubulavirus genus, its size ranging from 245-397 amino acid residues. 
Transcription gives rise to more than one mRNA species from the genomic region 
corresponding to the designated P gene. The V protein is translated from an mRNA in which 
the ORF (for the P region) is altered by editing. Studies of a V protein plasmid construct by 
Kato et al (1997) showed that the V protein is not essential for replication.
The V protein in SV5, a close relative to mumps virus, has been shown to inhibit interferon 
(IFN) signalling (Didcock et al 1999). The authors concluded that IFN inhibition allows the 
virus to replicate in vivo. The N-terminal region of the P protein contains protein 
phosphorylation sites (Vidal et al 1988) and regions essential for RNA synthesis, including a 
unique region for RNA encapsidation (Curran et al 1994). RNA editing in the morbillivirus 
genera also gives rise to another protein, designated the C protein. The C protein is a small 
protein which is located in the nucleus. Its function is unknown although both V and C 
proteins are expressed in infected cells (Bellini et al 1985).
1.3.3 The Matrix (M) Protein.
The M protein is membrane associated and plays a role in virion assembly. The nucleotide 
sequence for the M protein has been established for many paramyxoviruses (Blumberg et al 
1984, Chambers et al 1986, Afzal et al 1994). The M protein is synthesised by free 
ribosomes and is located beneath the viral lipid bilayer. It is a basic protein containing 
hydrophobic domains that are too small to span the lipid bilayer, thus concluding that the M 
protein is associated peripherally with the membrane.
The primary function of the M protein is thought to be structural, aiding the organisation of 
the virion prior to budding from the infected cell (Yoshida et al 1976, Matsumoto 1982). The 
MuV M protein associates with the cytoplasmic tails of the envelope glycoproteins, the lipid 
bilayer and the nucleocapsid. The M protein can also self-associate, a characteristic which is
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thought to be essential in budding virion formation.
Mottet et al (1996) observed that deletions in the SeV M protein hydrophobic region, 
resulting in an overall negative charge, prevented M protein self-association. Different 
deletions to give the M protein an overall positive charge increased self-association. In the 
persistent infection sub-acute sclerosing panencephalitis (SSPE) the MV M protein is 
produced at normal rates; however, it has been shown to be very unstable and dissociates 
rapidly. This rapid dissociation means that the virus is unable to bud and therefore the 
infection remains persistent (Hirano et al 1992). It has been shown that the M protein of 
wild-type MV can bind to the nucleocapsids of SSPE strains, concluding that M protein of 
SSPE viruses is defective in nucleocapsid-binding (Hirano et al 1993).
1.3.4 The Fusion (F) Protein.
As its name suggests, the F protein is involved in virus-to-cell and cell-to-cell fusion (Bratt 
and Gallaher et al 1969). It is one of the proteins responsible for the formation of large 
multi-nucleated cells, called syncytia, which are characteristic of mumps infection. The F 
protein is a classic type I  integral membrane protein, which is classified as having its N- 
terminus external to the virion and which spans the membrane once. Its structure consists 
of three domains; a large hydrophilic domain which is external to the virion, a domain of 
twenty uncharged amino acid residues which serves to anchor the protein to the membrane 
and a second hydrophilic domain located on the inside of the virion membrane.
The F protein is synthesised as a precursor Fq. This precursor is cleaved by a host cell 
protease, called Furin, into two biologically active units Fi and Fi which are linked by a 
disulphide bond (Scheid and Choppin 1977). Cleavage of Fo is essential for infectivity and 
pathogenicity.
The N-terminus of paramyxovirus Fi proteins has twenty hydrophobic conserved amino acid 
residues, termed the fusion peptide. The fusion peptide is usually hidden as part of an a- 
helix, except during fusion where conformational changes occur allowing exposure of the 
peptide to interact with the cell membrane (Chambers et al 1990). The same is also true for
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other viral fusion proteins, such as the influenza haemagluttinin (HA) protein (Chan et al 
1997), the HIV gp41 fusion protein (Joshi et al 1998) and the Ebola gp2 fusion protein 
(Russell et al 1994). There are many similarities between these fusion peptides; they are all 
homotrimers (Russell et al 1994) that require a conformational change to occur in order to 
become active. The F protein is glycosylated (Lambert 1988) and in MuV there are 
seven possible sites for N-linked glycosylation but to date there is no evidence to suggest 
which of these sites is used.
In order for syncytium formation to occur there has to be expression and interaction 
between the F protein and the HN protein (Tanabayashi et al 1992); this has also been 
observed for Newcastle disease virus (NDV) (Morrison et al 1991).
It is unknown how the fusion protein interacts with the cell membrane to cause cell fusion.
1.3.5 The Small Hydrophobic (SH) Protein.
The SH protein is present in MuV and SV5. It is a hydrophobic, integral membrane protein 
which is located in the plasma membrane (Takeuchi et al 1996). The function of the SH 
protein is unknown; deletion of the gene from an infectious cDNA clone of SV5 found that 
the SV5 virus could be successfully recovered. The authors concluded that the SH protein is 
not necessary for virus replication in tissue culture (He et al 1998).
Sequence analysis has shown that the SH gene is highly variable between strains of MuV 
and is a useful region of the genome for molecular epidemiological investigations. Analysis 
of sequence data generated for many MuV strains (Afzal et al 1997, Orvell et al 1997) 
suggests that the MuV isolates can be grouped into six genotypes A to F (Wu et al 1998, 
Tecle et al 1998). The data show that sequences within the ORF are highly variable but that 
there is a highly conserved region of approximately 50 nucleotides preceding the ORF 
translation initiation site.
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1.3.6 The Haemagluttinin-Neuraminidase (HN) Protein
The HN glycoprotein is a type I I  protein whose N terminus is located internally and spans 
the membrane once. Its function involves binding the virus to the host cell via sialic acid 
containing molecules on the cell surface (Markwell and Paulson 1980). This binding is strong 
and gives the virus the ability to agglutinate red blood cells of certain mammalian and avian 
species. The neuraminidase feature of the protein prevents self-aggregation of the virus 
after budding and also prevents re-adsorption back onto the infected cell. The HN protein is 
similar to the influenza neuraminidase (NA) protein, which is also a type I I  protein 
(Varghese et al 1983). The MuV HN protein is an oligomer consisting of disulphide bonds 
and forming tetramers. The site(s) for receptor binding is unidentified at present. It is 
suggested that HN protein binding to a receptor initiates a conformational change in the 
associated F protein releasing the hydrophobic fusion peptide into the target membrane 
(Stone-Hulslander and Morrison 1997).
The HN protein is a major antigenic determinant. It is the protein against which neutralising 
antibodies are raised. Studies using monoclonal antibody resistant (MAR) mutants have been 
conducted to determine the antigenic sites on the HN protein (Yates et al 1996).
1.3.7 The Large (L) Protein.
The L protein is the largest and least abundant of the viral proteins. The main role of the L 
protein is to play a part in the RNA-dependent RNA polymerase activity essential for viral 
transcription and replication. It is localised in the transcriptionally active viral core.
Nucleotide and amino acid sequences have been determined for many of the L protein 
genes of paramyxoviruses (Kawano et al 1991, Higuchi et al 1992). They are of similar 
length, approximately 2 , 2 0 0  amino acid residues, and there is little homology outside of the 
subfamilies. Towards the centre of the gene were found five regions of homology that are 
also conserved in other RNA-dependent RNA polymerases from other virus families (Poch et 
al 1990). These regions are assumed to be crucial for the enzymatic function of the protein. 
The P and L proteins combine to form a P-L complex which is required for polymerase
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activity with the NP-RNA template (Hamaguchi et al 1988). A transcriptionally active 
nucleocapsid contains 5 to 10 P protein residues per one L protein residue.
The L protein is also thought to be responsible for the addition of the polyA tail of the mRNA 
and the methyl-G capping of post-transcriptional mRNAs (Chinchar and Portner 1981).
1.4 Replication
For initiation of the infectious cycle, the virus must first enter a target cell. This is achieved 
by the virus surface glycoproteins attaching to the host cell receptor. The virus receptors are 
sialic acid containing macromolecules which occur on the host cell surface and specifically 
bind the virus (Markwell et al 1984). These macromolecules are common to most cells 
making viral entry possible to a variety of cell types. Two paramyxoviruses that do not use 
sialic acid containing molecules as receptors are respiratory syncytial virus (RSV) which 
binds to heparin sulphate (Feldmann et al 2000) and MV which uses a specific protein as a 
receptor (Naniche et al 1992).
After attachment, the viral membrane and host cell plasma membrane fuse at a neutral pH. 
This occurs through the interaction of the viral F protein with the host cell plasma 
membrane. The viral nucleocapsids are released into the host cell cytoplasm. The F protein 
must undergo a conformational change to become active. It is thought that, for MuV, this 
change occurs through interaction with the HN protein. The events of viral entry have been 
studied more extensively for the case of influenza virus (Klenk et al 1975). After attachment 
to the host cell via the sialic acid receptors, the influenza virus is internalised by receptor 
mediated endocytosis. After endocytosis has occurred, the influenza virus is transported to 
the lysosomes where an acidic pH environment causes an irreversible conformational change 
in the HA protein. This viral entry pathway is of interest for antiviral drug design.
The next stage in the cycle is transcription of the negative sense genomic RNA into mRNA. 
Paramyxoviruses use a single transcriptional unit with one promoter sequence. In 
Rubulaviruses, the 3' end of the genome and the first gene, the NP gene, are separated by 
55 nucleotides, the leader sequence. The first twelve nucleotides of the leader sequence are
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conserved throughout the Paramyxoviruses. The viral P-L polymerase initiates the 
transcriptional process at the 3' end of the RNA and, after transcribing the leader sequence, 
the viral polymerase terminates and reinitiates transcription at the beginning of the first 
gene. Reinitiation of transcription after each termination sequence is not 100%, leading to a 
higher production of mRNA's located near to the leader sequence in comparison to L mRNA, 
the farthest from the leader sequence. Bicistronic and polycistronic mRNA's are also 
produced. By doing this the virus can control the relative levels of mRNA production.
The switch from transcription to replication is not well understood. Pattnaik et al (1995) 
showed that the signals needed for RNA replication are contained within the 36 nucleotides 
at the 5' genomic end of VSV. Whelan and Wertz (1999) concluded that elements at the 3' 
end are essential for transcription, but not replication. Abolishing the leader sequence 
promoted replication concluding that the leader sequence is less efficient as a promoter for 
replication than the trailer sequence.
Replication of the negative sense genome requires a full-length positive sense intermediate 
cRNA generated by the viral polymerase which copies the RNP template ignoring 
transcription stop signals. Kolakofsky and Ortin (1991) suggested this override could be 
caused by the levels of NP and RNA synthesis occurring concomitantly. With low levels of 
unassembled NP present, the polymerase preferentially engages in mRNA synthesis to raise 
the levels of all virus proteins. If levels of unassembled NP are high, the polymerase 
preferentially engages in genome replication. Genomic RNA synthesis is thought to occur in 
the same way as antigenome synthesis.
Nucleocapsids assemble in the cell cytoplasm resulting in the production of the helical RNP 
complex (Kolakofsky et al 1998). After RNP assembly, interaction with the P-L complex 
occurs. Proteins are transported through the ER and Golgi apparatus. Once all the proteins 
have been post-translationally modified, they assemble together near the surface of the host 
cell. This is achieved in paramyxoviruses by altering the chemical composition of an area of 
the plasma membrane making it more rigid. Viral glycoproteins are inserted into this area of
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the membrane. The matrix protein accumulates on the inside of the membrane at this point 
and mediates interaction with the RNP. The whole complex then buds away from the plasma 
membrane into the intracellular environment. (Harper 1994)
1.5 Reverse Genetics of Paramyxoviruses
Viruses and their interactions with host cells are of great interest to the virology community. 
Within the past decade scientists studying mumps and other negative strand viruses and
these interactions have had the benefit of a technique called Reverse Genetics -  the ability
to recover infectious virus from cloned DNA.
Genomic manipulations of viruses which use DNA as their genetic material were the first to 
be conducted in order to 'rescue' a virus in vitro. This recovery can be achieved either by 
transfecting cells with plasmids encoding the viral genome or by heterologous recombination 
of plasmids bearing sequences of the virus genome.
Rescuing infectious positive strand RNA viruses such as poliovirus, requires either the 
introduction into cells of in vitro synthesised RNA from cDNA or intracellular expression of 
RNA following DNA transfection. The plasmid-based reverse genetics technology was 
established for DNA and positive strand RNA viruses with relative ease.
The genomes of the negative strand RNA viruses have been less amenable to artificial 
manipulation for several reasons: (i) the viral RNA itself is non-infectious: (ii) precise 5' and 
3' ends are required for replication and packaging of the genomic RNA: (iii) the viral RNA 
polymerase is essential for transcribing both mRNA and the cRNA intermediate; and (iv) 
both genomic and antigenomic RNA's exist as RNP complexes, which are crucial to the 
initiation of the viral life cycle. Virus rescue from cDNA for MononegaviraieshdiS required 
years of development, much of which is still ongoing.
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Figure 1.2; Diagrammatic representation of Paramyxovirus replication.
Detailing the two courses MuV RNA takes after penetration of the host cell membrane, all of 
which takes place within the cytoplasm of the infected cell.
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The phenotypes of rescued viruses can be studied and defined in the context of not only 
viral replication in vitro but also in iVi/D viral multiplication and pathogenesis. With the aid of 
reverse genetics, researchers can address pending scientific questions which could not be 
addressed through conventional virology, for example in determining the function of the 
paramyxovirus accessory genes, C and V. Reverse genetics has opened many possibilities in 
the field of viral vaccine research; the designing of live viral vaccines with predetermined or 
plausible attenuating mutations and reducing the time needed to generate new vaccine 
viruses to a few weeks rather than the months or years that are required using conventional 
approaches. The technology required to produce an infectious clone of the mumps virus is 
now well established (Clarke et al 2000) and can be used in structure related functional 
studies as well as designer vaccines.
1.6 Clinical Symptoms of Mumps Infection
Mumps is an acute infectious disease which spreads through respiratory droplets. The 
disease can vary from a mild upper respiratory illness to viraemia with widespread systemic 
involvement (Table 1.3). Classic mumps is characterised by the enlargement of the parotid 
and other salivary glands (Baum and Litman 1995), although infection is asymptomatic in 
about one third of cases. Up to 10% of mumps patients develop aseptic meningitis. A less 
common but more serious complication is encephalitis, which can result in death or 
permanent disability. Deafness, orchitis and pancreatitis are other untoward effects, all of 
which are preventable through vaccination (Galazka et al 1999).
The clinical consequences of systemic infection can be quite severe if the illness is delayed 
until adulthood. Twenty-five percent of adult men who contract mumps suffer from 
epididymo-orchitis, the median age for which is 29 according to a large cohort study 
conducted in 1977 (Beard et al 1977). A further one-third of patients suffering from mumps 
orchitis also develop testicular atrophy, though complete sterility is rare.
A possible link between mumps orchitis and testicular cancer has been demonstrated, 
though it is not considered to be a major cause but a risk factor (Swerdlow et al 1987). In
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adult women, mumps mastitis and oophoritis can occur. A study by Philip et al (1959) 
showed that mumps mastitis occurs in 31% of women over the age of 14. Twenty-five 
percent of women who acquire MuV during the first 12 weeks of pregnancy suffered from 
spontaneous abortion, a rate which supercedes that due to rubella infection (Siegel et al 
1966). Pancreatitis occurs in 4% of clinical mumps patients, with evidence to suggest that 
MuV infection of the human pancreatic beta cells can trigger the onset of insulin-dependent 
diabetes mellitus in some individuals (Stratton et al 1994).
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Table 1.3 : Clinical manifestations of mumps (modified from Baum and Litman 1995).
Manifestation Frequency (% )
Glandular
Parotitis 60-70
Submandibular and/or sublingual adenitis 1 0
Epididymo-orchitis 25 (Post-pubertal men)
Oophoritis 5 (Post-pubertal women)
Pancreatitis 4
Neurological
Aseptic meningitis 1 - 1 0
Encephalitis 0.02-0.3
Other
Miid Renal function abnormalities 30-60
Electrocardiagram abnormalities 5-15
Deafness (usualiy transient) 4
35
Using saliva from an infected patient, meningoencephalitis was reproduced in macaques 
inoculated by the intracerebral (i.c) route as far back as in 1934 (Gordon 1934), and before 
the widespread use of a mumps vaccine, MuV was among the most common causes of 
hospitalisation from meningitis (Russell and Donald 1958).
Up to 10% of mumps patients develop aseptic meningitis and, for unknown reasons, more 
often in males than females. Mumps meningitis is clinically manifested by a severe headache 
that is aggravated by movement, photophobia and neck stiffness due to spasms of the 
spinal muscles (Grist 1993). This is a benign condition that appears within a few days of 
parotid sweliing; however, not all meningitis patients exhibit parotitis. Mumps meningitis 
patients generally recover without complications, though many require hospitalisation for the 
duration of the illness. In Sweden during the pre-vaccine era, it was estimated that, 
annually, mumps caused approximately 1000 meningitis cases. This in turn led to 20,000 
days of hospitalisation and 20,000-40,000 days of disability (Bjorvaten and Skoldenberg 
1979). The incidence of mumps encephalitis is reported to range from 1 in 6000 mumps 
cases (Russell and Donald 1958) to 1 in 300 mumps cases (CDC 1974). Encephalitis 
symptoms range from mild alterations of consciousness to coma, emotionai liabiiity and 
irritability. For as yet unknown reasons, mumps encephalitis affects three times as many 
men as women (CDC 1974).
A well-recognised complication of mumps infection is deafness. In Finland, 298 military 
personnel who contracted MuV were assessed for deafness using audiometric tests. The 
results showed that 13 (4%) had high frequency hearing loss. The hearing loss reverted 
within a few weeks for 12 but one progressed to permanent deafness (Vuori et al 1962). 
Further clinical symptoms observed with MuV infection include mild renal function 
abnormalities (Utz et al 1964) that generally resolve spontaneously. Transient 
electrocardiogram abnormalities occur in 15% of cases (Rosenberg 1945) with a rare case of 
fatal myocarditis also having been reported (Ozkutiu et al 1989).
Fatality attributed to MuV is exceedingly rare and when it occurs is mainly due to mumps
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encephalitis. In the USA, from 1966-71, there were two deaths per 10,000 mumps cases 
with 38% of such deaths involving persons aged >40 years (CDC 1974). In the UK, 93 
deaths were registered from mumps over the period 1962-81 with 53 (57%) of those who 
died being aged >45 years (Galbraith et al 1984).
1.7 Mumps Vaccines History
Aii mumps vaccines consist of a iive attenuated strain of virus. Live attenuated mumps 
vaccines are available as monovalent mumps vaccine, bivalent measles-mumps, MM, vaccine 
and trivalent measles-mumps-rubelia, MMR, vaccine. World Health Organisation (WHO) 
requirements do not specify the minimum amount of mumps vaccine virus that one human 
dose should contain; rather, this is determined by the national control authority of the 
country where the vaccine is licensed (WHO Tech Rep 1994). The majority of countries use 
1000 Tissue Culture Infectious Doses 50% (TCID50 -  meaning the dose required for 50% of 
tissue culture cells to be infected with the virus) of attenuated mumps virus per dose. Live 
mumps vaccines are produced as iyophilised powder and once they have been reconstituted 
with sterile water they must be used immediately or stored at 0-8°C away from light and 
discarded within 8  hours (WHO Tech Rep 1994).
Since its introduction, several strains of MuV have been used in the mumps vaccine. In the 
UK, the MMR vaccine currently contains the attenuated Jeryl Lynn (JL) strain, named after 
the child from whom it was isolated in 1965. The virus was attenuated by passaging in 
embryonated hens eggs and subsequently in chick embryo cell culture (Buynak and Hilleman 
1966). The strain was licensed in 1967 and by 1992 it had been administered to over 135 
million children and adults worldwide (WHO Tech Rep 1994). Clinical studies undertaken in 
industrialised countries have shown that one dose of the JL strain of mumps vaccine leads to 
an initial seroconversion rate of 80-100%, which increases to 97-100% with two doses 
(Fahlgren 1988). Further studies documented antibody persistence in a large proportion of 
vaccinees. A Swedish study found that 73% of children who received two doses of the MMR 
vaccine containing the JL strain at 18 months of age remained seropositive 10.5 years later
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(Broliden et al 1997). The protective efficacy of 1 dose of the JL strain in vaccine outbreak- 
based studies has ranged from 75-91% (Cochi et al 1994). There are few figures for JL 
vaccine efficacy in developing countries; however, a study in the Dominican Republic 
reported a 94% seroconversion rate among 72 seronegative children aged 1-6 years old 
(Ehrenkranz et al 1975).
In studies of vaccine associated adverse events in the United States of America (USA), a 10 
year study of hospitalised cases in a cohort of children due to MuV infection found one case 
of aseptic meningitis per 100,000 doses of JL containing MMR vaccine (Biack et al 1997). In 
Germany, the JL strain was associated with 0.1 aseptic meningitis cases per 100,000 vaccine 
doses (Fescharek et al 1996). These reports conclude that there is a risk of developing 
aseptic meningitis from the mumps component of the MMR vaccine however the incidence is 
very low. Many other strains of attenuated MuV have aiso been used in vaccines. The live 
attenuated Urabe strain of MuV was first licensed in Japan in 1979 and thereafter in 
Belgium, France, UK, Canada and Italy (WFIO Tech Rep 1994). It was attenuated by serial 
passaging in the amnion of embryonated hen's eggs. By 1991, more than 60 million people 
worldwide had been immunised with this vaccine (WHO Tech Rep 1994).
A Finnish study of children who received a mumps vaccine at 14-20 months of age showed 
95% seroconvertion with the Urabe vaccine as compared to 97% with the JL vaccine 
(Vesikari et al 1983). Studies that assessed the immunogenicity of the Urabe vaccine among 
seronegative children in developing countries reported 99% seroconversion in Brazil (Forleo- 
Neto et al 1997) and 98% in South Africa (Schoub et al 1990). A Canadian study reported 
that 5-6 years after one dose of MMR vaccine the seropositivity rate was 93% for the Urabe 
vaccine, compared with 85% for the JL vaccine (Boulianne et al 1995).
The fears that some children developed aseptic meningitis after receiving the Urabe 
containing MMR vaccine initiated a study using molecular tools to investigate any possible 
relationship between the vaccine and associated adverse events. Spinal fluid analysed from 
vaccinees who developed aseptic meningitis confirmed the association of the Urabe strain to
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the disease (Brown et al 1996). This led to Urabe containing MMR vaccines being withdrawn 
from the market in Canada by 1990 (Furesz and Contreras 1990).
Following this report, the UK conducted studies into the rates of aseptic meningitis that were 
attributable to the use of the Urabe vaccine. A small study in Nottingham was followed by a 
multi-centre confirmatory study that confirmed 9 cases of aseptic meningitis per 100,000 
vaccine doses (Miller et al 1993), as a result of which the UK Public Flealth Service 
Department stopped purchasing the Urabe vaccine in 1992.
The Rubini strain of mumps vaccine was attenuated by passaging in MRC-5 human diploid 
cells followed by serial passaging in embryonated hen's eggs and then adaptation back to 
the MRC-5 cell line (Glück et al 1986). In 1985, Switzerland licensed a mumps vaccine based 
on the Rubini strain and by 1990 it had been used to vaccinate over 4 miilion people 
worldwide (WHO Tech Rep 1994). A study conducted in Switzerland provided evidence that 
the Rubini mumps vaccine did not offer long-term protective immunity against the disease. 
The study found an efficacy rate of 6% over 16 years, compared to 62% for the JL strain 
and 73% for the Urabe strain (Chamot et al 1998).
The attenuated Leningrad-3 (L-3) vaccine was developed in the former Soviet Union in 
guinea-pig kidney cell cultures (Smorodintsev et al 1970) and subsequently licensed in 1974 
in the USSR. Approximately 8-11 million doses of the L-3 vaccine were produced annually 
(WHO Tech Rep 1994). Studies on seroconversion and the efficacy of the L-3 vaccine 
showed a 89-98% seroconversion rate and a protective efficacy of 92-99% (Smorodintsev et 
al 1970). In Slovenia, passive surveillance from 1979-1985 identified 20 cases of aseptic 
meningitis per 100,000 doses of MM vaccine containing the L-3 strain (Kraigher 1990). The 
Leningrad-Zagreb (L-Zagreb) strain was produced in Croatia by further adapting the L-3 
MuV through passage on CEF cells (Beck et al 1989). Over the period of 1975-87, more than 
10 miilion doses of L-Zagreb mumps vaccine were distributed in the former Yugoslavia (Beck 
et al 1989). Studies in Croatia conducted on L-Zagreb vaccine showed 87-100% 
seroconversion and an efficacy of 97-100% (Beck et al 1989). However, there were 90 cases
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of aseptic meningitis per 100,000 doses of L-Zagreb containing MMR vaccine over the period 
of 1988-92.In Slovenia, MMR vaccines containing the L-Zagreb mumps strain have been 
used since 1990. Passive surveillance over the period 1990-96 revealed two cases of aseptic 
meningitis per 100,000 doses (Kraigher 1990).
Mumps was a common infectious disease in the pre-vaccine era, with a high annual 
incidence >100 per 100,000 population based on routine passive surveillance (Table 1.4) 
whilst incidences greater than 6000 cases per 100,000 have been reported in military 
populations (Gordon and Kilham 1949). Countries which lack a mumps vaccination program 
display a high incidence of the disease, with epidemic peaks occur every 2-5 years with the 
infected majority being those aged 5-9 years.
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Table 1.4: Average annual reported mumps incidence in the WHO European Region 
before and after the introduction of mumps vaccine including two countries with no 
mumps vaccination (Adapted from Bakasun 1997).
Country Pre-vaccine
Years Average annual 
Incidence *
Post- vaccine
Years Average 
Annual 
Incidence
%  Reduction
Two-Dose 
Schedule
Denmark 1977-79 726 1993-95 1 >99
Finland 1977-79 223 1993-95 <1 >99
Norway 1977-79 371 1993-95 11 97
Slovenia 1977-79 410 1993-95 4 >99
Sweden 1977-79 435 1993-95 <1 >99
One-Dose
Schedule
Armenia 1983-85 280 1993-95 16 94
Croatia 1983-85 101 1993-95 12 88
England and 1983-85 40 1993-95 5 88
Wales
Israel 1983-85 102 1993-95 10 90
Latvia 1983-85 141 1993-95 3 98
No Mumps 
Vaccine
Poland 1983-85 415 1993-95 361
Romania 1983-85 242 1993-95 217 -
*  cases per 100,000 population
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Prior to the introduction of mumps vaccine, serosurveys conducted to assess population 
immunity to MuV showed that protective maternal antibody is passively transferred to the 
infant, but only has a half-life of 35-40 days. Data collected from England and Wales 
(Morgan-Capner et al 1988), the Netherlands (Wagenvoort et al 1980) and Singapore (MMR 
Report 1992) document an increase in mumps antibody level from the age of 2-3 years; by 
4-6 years of age 50% of children had acquired natural antibodies and by 14-15 years of age, 
90% of the population was seropositive. It is not recommended to administer mumps 
vaccines to immunosuppressed individuals or to pregnant women due to the theoretical risk 
of foetal damage, and pregnancy should be avoided for a minimum of three months post­
vaccination (Morb and Mort Rep 1998).
In recent years, there has been much speculation as to the relative safety of MMR vaccine.
A report published by Wakefield et al in 1998 raised concerns of a possible link between the 
persistence of MV in the gut and inflammatory bowel disease (IBD). Since then, many 
scientific teams have researched this daim. Teams using highly sensitive and specific 
reverse transcription polymerase chain reaction (RT-PCR) methods to examine colonic 
biopsies from newly diagnosed and treated Crohn's disease patients and resection 
specimens, targeting various regions of the MV genome, N, F, M and Fi genes, found no 
evidence of MV in the gut (Haga et al 1996, Afzal et al 1998a, 1998b, 2000, Chadwick et al 
1998). There are reports in support of the Wakefield et al claim (Kawashima et al 2000). 
Flowever, a lot of the results are inconsistent and there is overwhelming research and 
epidemiological evidence to the contrary (Davis et al 2001).
Wakefield et al (1998) also suggested a relationship between MMR vaccine and autism. 
Autism is a syndrome of unknown aetiology and many factors have been considered to be 
potential risks, including environmental influences, genetic predisposition, viral infection and 
immunological reactions (Deykin 1979, Singh 1994, Folstein and Rutter 1988).
Evidence for the presence of auto-antibodies to myelin basic protein (MBP) in autistic 
individuals has been shown (Singh et al 1993). These authors also showed that 90% of
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measles IgG positive autistic sera contain anti-MBP antibodies, suggesting a link between 
vaccination and autism. Chicken MBP residue could be present in MMR vaccine preparations 
as the vaccine is propagated in cells derived from eggs and antibodies against chicken MBP 
can cross react with human MBP. However, Afzal et al (2001) found a lack of chicken MBP 
residues in any commercial formulations of MMR vaccine. Signs of the autism syndrome 
appear around 15-20 months of age, which coincides with the recommended age of MMR 
vaccination (MMWR, 2000). Although there has been overwhelming scientific evidence 
showing the lack of a possible relationship between MMR vaccination, IBD and juvenile 
autism, the faith of the public on MMR vaccine safety remains low causing a decline in 
vaccine uptake at a national level. It is possible that if the vaccine uptake does not improve 
significantly then the UK may encounter an epidemic of measles, mumps and rubella.
1.8 Neurovirulence of Mumps Virus and Mumps Vaccines 
Mumps virus is a neurotropic virus of humans (Zuker 1975) with up to 10% of mumps 
infected patients developing meningitis, and encephalitis due to MuV occuring in up to 0.3% 
of infected patients. Mumps meningitis involves the meninges and can often take an 
asymptomatic course (Ocklitz 1976). The involvement of the central nervous system during 
mumps infection has been one of the major reasons for developing preventative 
immunisation against this infection. Consequently the neurotropic nature of the vaccine virus 
must be considered when assessing the safety of live mumps vaccines and a reliable 
neurovirulence test is, therefore, desirable. Such testing is a requirement as stipulated by 
the European Pharmacopoeia and health organisations of countries with mumps vaccination 
programmes. Experiments conducted on hamsters (foetal, newborn and adult) showed that 
pathogenic wild-type and vaccine derived MuV has a high tropism towards the ventricular 
ependyma with the possibility of hydrocephalus development (Johnson et al 1967, Johnson 
and Johnson 1969, 1972, Kilham and Margolis 1975). An aetiological role of MuV in 
hydrocephalus in man is also suspected (Timmons and Johnson 1970, Bray 1972, Johnson 
and Johnson 1972). In 1979, Levenbruk et al performed experiments on monkeys using
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variants of attenuated MuV. These viruses retained a more or less substantial degree of 
virulence which was indicated by the specific morphological lesions localised away from the 
inoculation site. At a higher attenuated passage level, they obtained a variant causing much 
more pronounced changes in the brain ventricular system. This variant was regarded as the 
variant with the greatest risks, from the viewpoint of its higher tropism towards the 
ventricular structures.
1.9 Structure of the Brain
The vertebrate brain is divided into three regions; the forebrain, the midbrain and the 
hindbrain. Each of these regions receives and analyses sensory information from a particular 
type of sensory receptor. For example, the forebrain receives chemical information from the 
nose via the olfactory nerves, the midbrain receives visual information from the eyes via the 
optic nerve, and the hindbrain receives vibration and orientation information from the ears 
and balance organs via the auditory and vestibuiar nerves, respectively. Each of these 
regions contains groups of neuronal cell bodies which are collected together to serve a 
particular function. The centrai core of the midbrain and the hindbrain is called the brain 
stem.
1.9.1 The Ventricles
The ventricles are the remnants of the tube of hollow fibres from which the brain developed. 
They lie deep inside the forebrain, midbrain and hindbrain in a series of inter-connecting 
chambers iined with an epithelium called ependyma. These ventricles are filled with a liquid 
called the cerebrospinal fluid (CSF), which also surrounds the brain, functioning to cushion it 
from knocks. CSF is constantly produced and percolates through and fills the ventricles. It 
leaves the system by flowing out of three openings from the fourth ventricle. The CSF does 
not contain red blood cells and its composition is different from the composition of the fluid 
part of the blood, plasma. This difference is the resuit of the activity of special cells which 
form what is known as the blood-brain-barrier. The existence of the blood-brain barrier
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protects the neurons in the CNS from harmful substances; it also affects how easily drugs 
can enter the extracellular environment of the CNS.
1.10 Neurovirulence Testing of Live Viral Vaccines
Live viral vaccines must undergo neurovirulence testing before being released onto the 
general market. One of the objectives in regulating medicinal products is to control the 
safety and efficacy of material being administered. This is essential in order to document 
any adverse events prior to distribution.
1.10.1 Yellow Fever (YF) Vaccine
Neurological complications arising from the 17D strain of yellow fever vaccine have been 
well documented (Fox and Penna 1943), and a monkey safety test is used to assess the 
neurovirulence of YF vaccine virus. This test is based on the clinical manifestations of 
encephaiitis observed in i.c inoculated monkeys (WFIO Tech Rep 1976). Various seed viruses 
prepared from different passage levels of this strain displayed different degrees of 
neurovirulence in monkeys when inoculated into the CNS. One human dose of the vaccine 
(5000-50,000 Mouse Lethal Dosesso) is inoculated into the frontai lobe of the monkey brain. 
The monkeys are observed for a period of 30 days for signs of encephalitis. According to 
WFIO requirements (1976) the vaccine has an acceptable degree of neurovirulence if not 
more than 10% of inoculated monkeys develop severe signs of encephalitis; these include 
paralysis, inability to stand when stimulated or death. In addition, the test virus must not 
induce other signs of encephalitis, such as incomplete paralysis, incoordination, tremors, 
lethargy, inability to stand spontaneously, motor weakness or spasticity, at a frequency 
greater than that induced by a laboratory reference vaccine with acceptable properties in 
man and monkey. A grading method is used in order to assign a numerical value to the 
severity of the clinical signs exhibited. The accepted current grading method was developed 
by Levenbook et al (1987) and is based on observations of monkeys inoculated with YF 
vaccine virus:
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Grade 1: rough coat, not eating
Grade 2: high pitched voice, apathetic, inactive, slow moving, general weakness.
Grade 3: shaky, tremors, uncoordination, limb weakness.
Grade 4: inability to stand, upper or lower limb paralysis, or death.
1.10.2 Live Polio Vaccine
The oral polio vaccine (OPV) has a well documented viral neurovirulence test and the 
vaccine is used throughout the world in the WHO initiative to eradicate the disease, 
poliomyelitis. A high degree of attenuation is a basic requirement for OPV. Assessing the 
degree of attenuation of the three subtypes of poliovirus (1, 2 and 3) is achieved by 
inoculation of a test virus into the CNS of monkeys. The monkey neurovirulence test (MNVT) 
has played a crucial role in the development and maintenance of the live vaccine and the 
MNVT has proven to be a sensitive test which assures the safety of OPV in humans 
(Contreras et al 1988). In 1982, a new standardized MNVT for the control of OPV was 
developed and adopted by the WHO (WHO Tech Rep 1990). An MNVT on each monovalent 
bulk of OPV is a mandatory requirement of the WHO and the national authorities. This 
differs from mumps vaccines where it is only the seed stock that requires neurovirulence 
testing and not each bulk. However, the use of the large numbers of monkeys required in 
each MNVT poses increasing ethical problems, health risks to animal keepers and high costs. 
In light of these disadvantages it would be desirable to replace monkeys with an in vitro 
test.
In 1989-1990, two groups of scientists (Ren et ai 1990, Koike et al 1991) with the support of 
the WHO Vaccine Development Program, genetically engineered mice to make them 
susceptible to poliovirus. These mice were designated TgPVR mice -  transgenic for the polio 
virus receptor. Both groups recommended these animals to replace the monkey model for 
investigation of poliovirus neurovirulence attenuation. In 1991, the WHO recommended that 
a study be conducted in order to compare the suitability of replacing monkeys with TgPVR 
mice and the USA Food and Drug Administration (FDA) was chosen as the focal point for
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this project. The study conducted on the i.c inoculated TgPVRl mouse line indicated that 
this mouse system could differentiate between the wild-type Leon/37 strain, the Sa bin 
vaccine strain and a substantially neurovirulence-reverted clone of the vaccine virus isolated 
from a stool sample (Dragunsky et al 1993). However, the TgPVRl mice were unable to 
discriminate between type-3 vaccine batches that passed or failed the MNVT (Dragunsky et 
al 1997). The intraspinal (IS) inoculation route proved to be no more effective than the IC 
route. Another mouse line, TgPVR21, was examined. This mouse line has a reduced number 
of transgene copies, which is shown by the lower levels of PVR mRNA and membrane 
associated PVR protein in the CNS compared to the TgPVRl mice (Koike et al 1991). In the 
MNVT, the acceptance/rejection decision of a vaccine batch is based on the scoring of 
specific histological lesions in the CNS of monkeys (WHO Tech Rep 1990). By contrast, the 
TgPVR21 mouse neuroviruience test detected those OPV lots that failed the MNVT by 
evaluation of clinical signs of poliomyelitis, thus not requiring the laborious histological 
examination of the CNS (Dragunsky et al 1997).
A large collaborative study of type-3 OPV demonstrated, with statistical reliability, that the 
TgPVR21 mice provided as sensitive and reproducible a test for neurovirulence of OPV as 
the monkey test (Levenbook et al 2000). A statistical decision model for the 
acceptance/rejection decision of type-3 vaccines using the transgenic mouse test has been 
developed. The transgenic mouse neurovirulence test demonstrates a number of advantages 
over the monkey neurovirulence test:
1) Ethical and practical considerations for reduction of number of primates used in the 
test
2) Elimination of hazards to personnel working with the primates
3) Use of a special line of mice with highly defined genetic and microbiological quality 
standards
4) Significantly shorter time required for the test -  2 weeks for the mouse test instead 
of 1.5-2 months for the monkey test
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5) Strictly objective evaiuation of the test results -  observation of paresis/paralysis 
versus semi-subjective scoring of histological lesions in the CNS of monkeys.
6) Reduction in the costs of control tests for OPV.
1.10.3 Live Mumps Vaccine Virus
In the pre-vaccine era, MuV was the leading cause of virus-induced CNS disease; a disease 
which has since declined due to the introduction of a mumps vaccination programme. 
However MuV complications in vaccinees were reported (Cizman et al 1989, Miller et al 
1993). These adverse events are thought to be due to insufficient attenuation of 
neurovirulent vaccine virus strains. Consequently neurovirulence tests are a required part of 
mumps vaccine seed evaluation. However, there is a lack of a reliable animal model with 
which to test mumps virus neurovirulence which in turn has led to an inability to predict 
accurately the effect of a vaccine strain on humans, as well as hindering studies into the 
neuropathogenesis of MuV infection and identification of the virologicai determinants of 
neurovirulence.
Neurovirulence is measured by scoring histological lesions present in the CNS of virus 
inoculated monkeys. Observations by Bunyak and Hilleman in 1966 showed that this system 
did not always yield a valid result. The authors observed that vaccine and virulent mumps 
viruses often produced similar histological lesions.
Recent studies into the use of the marmoset monkey in the MNVT has yielded surprising 
results. Saika et al (2002) demonstrated that histological examination of the CNS of i.v 
inoculated marmoset monkeys could distinguish between virulent and non-virulent strains of 
MuV. The authors also showed that the marmosets displayed symptoms of nephritis, 
parotitis, pancreatitis and tonsillitis.
The severity of mumps virus histological lesions in the monkey model is evaiuated using 
grades 1-4 (Afzal et al 1999a)
Grade 1: Minimal. Very mild infiltration of the subependymal zone of the ventricular wall and
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very mild diffusion of the choroid plexus. Slight degree of focal dystrophic lesions as well as 
proliferation of the ependymal cells.
Grade 2 : Moderate. Mild infiltration of the subependymal zone with moderate diffuse 
infiltration of the choroid plexus, moderate degeneration and proliferation of the ependymal 
cells.
Grade 3 : Severe. Severe significant focal infiltration with more diffuse areas of dense 
infiltration in up to one half of the ventricular wall, subependymal oedema; severe 
infiltration in the choroid plexus; degeneration in some areas of the ependyma and 
proliferation in others with papiiiomatous formations.
Grade 4 : Overwhelming. Severe inflammatory infiltration of more than one half of the 
ventricular wall and in the choroid plexus; loss of ependymal epithelium, adhesion of the 
inflamed choroid plexus to the ventricular wall.
1.10.4 Monkey Neurovirulence Test for Mumps Virus
The MNVT is required by the WHO, the EP and National Control authorities for the 
evaluation of the neurovirulence potency of the vaccine seed stock and the first five 
consecutive lots of mumps vaccines (WHO report 1994). This aims to provide assurances to 
the vaccine manufacturer and control authorities regarding the clinical safety of the vaccine 
progenitor material, although it does not ensure freedom from possible instability of virus 
attenuation during vaccine manufacture. There is no explicit protocol for the mumps vaccine 
MNVT.
Levenbook et ai (1979) obtained convincing data which demonstrated a strong correlation 
between the MNVT for L-3 vaccine and vaccine-associated meningitis in children. In the 
neurovirulence test required by the WHO and the EP, the inoculum is injected into the 
thalamus region of mumps seronegative macaques that are then monitored 17-21 days for 
signs of CNS disorders or any other abnormal symptoms. At the end of the observation 
period, the tissues are subjected to histopathologicai examination. Ventricular and 
periventricular areas of the brain demonstrated keen histopathologicai responses to the
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inoculation of MuV, thus the neurovirulence test was revised to concentrate assessment on 
these regions (Maximova et al 1996). Using the revised test, Afzal et al (1999a) examined a 
variety of mumps strains, both wild-type and vaccine strains, for neurovirulence. Their study 
concluded that the test had the ability to distinguish between wild-type and vaccine strains 
but not between mixed and unmixed populations or a putative neurotropic strain from its 
attenuated bulk precursor. Thus, ability of the test to discriminate between acceptable and 
unacceptable seed lots requires further examination.
1.10.5 Rat Neurovirulence Test
A rat model has been investigated as an alternative to the use of monkeys for 
neurovirulence testing. Viral infection during foetal development has been linked to 
abnormalities in the CNS and these are a major form of congenital defect in humans (Behan 
1985, Brouwers et al 1995). Viral infections known to cause intrauterine or postnatal brain 
developmental damage include herpes simplex virus (Beers et al 1995), HIV (Brouwers et al 
1995), rubella and mumps virus (Rubin et al 1998). The rat brain continues to mature after 
birth and is vulnerable to developmental damage following perinatal insult. It is a reasonable 
assumption that at this stage a neurotropic virus will incur the maximum amount of damage 
giving a worse case scenario of what may occur during viral infection of the human brain. 
The use of smaller animal models is a major consideration of modern day vivisection, but 
not at the cost of compromising the efficacy of the tests. By developing a model for 
neurovirulence on a smaller animal like the rat, or transgenic mouse as for OPV, it may be 
possible to improve the current test. The rat model has been shown in a number of cases 
with viruses to exhibit accentuated brain damage making it easily readable histologically. 
Rubin et al (1998) demonstrated that a neonatal rat model could distinguish between 
virulent and non-virulent strains of MuV. In 2000, Rubin et al suggested that the human 
neurovirulence of the MuV strains was proportional to the severity of the hydrocephalus in 
rats, but not in the lesion scores in monkeys, making the neo-natal model suitable for 
further evaluation.
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1.11 study Objective
Some commercial mumps vaccines have been shown to be problematic when used for large 
scale immunisation. The most common adverse effects reported following mumps/MMR 
vaccination is the development of aseptic meningitis within 8-30 days post-immunisation. All 
MuV vaccine strains, with the exception of the JL strain, have been attributed to post­
vaccination meningitis at a variable rate. Previous work conducted at NIBSC in relation to 
the evaluation of the monkey model for mumps vaccine neurovirulence testing concluded 
the unsuitability of the model for various reasons described in previous sections. Similar 
conclusions were also drawn by a team working independently at the FDA in the USA. 
Additionally, the FDA have developed a neo-natal rat model for mumps virus neurovirulence 
testing that needed to be evaluated at an independent laboratory.
The current study evaluates the neo-natal rat model by using a variety of mumps virus 
vaccine, vaccine derived and wild-type strains, to assess its susceptibility in discriminating 
between strains that are predicted to have diverse neurovirulence. The majority of strains 
used in this study were tested in the monkey model previously and the study therefore is 
capable of comparing the rodent model and the primate model directly.
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2 Materials and Methods
2.1 Materials
2.1.1 Cell Culture Medium and Solutions 
Eagle's Minimum Essential Medium (MEM): Sigma
0.97g MEM in 100ml distilled water pH 7.0
Penicillin and Streptomycin: 1.25g penicillin-G sodium salt, Ig  
streptomycin sulphate in a final volume of 
100ml distilled water
Fungizone: 0.02g Fungizone in a final volume of 
100ml distilled water
Bicarbonate stock: 4.4g NaHCOs, 0.5g phenol red in a final 
volume of 100ml distilled water
L-Glutamine Stock: 2.9g glutamine in a final volume of 100ml 
distilled water
Foetal Calf Serum (FCS) Sigma
Growth Medium: 3% (v/v) bicarbonate stock 
1% (v/v) penicillin and streptomycin 
1% (v/v) fungizone 
4% (v/v) FCS 
in MEM pH 7.0
Maintenance Medium: 3% (v/v) bicarbonate stock 
1% (v/v) penicillin and streptomycin 
1% (v/v) fungizone 
1% (v/v) FCS
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PBS
in MEM pH 7.0
1.07g NaCI 
0.03g KCI 
0.017g CaCIz.ZHzO 
0.013g MgCIz.GHzO 
0.40g NazHPO .^lZHzO 
0.03g KH2PO4
in a final volume of 100ml distilled water 
pH 7.4
Trypsin stock: Sigma
6mg trypsin in 100ml saline solution
EDTA stock: 0.4g EDTA in a final volume of 100ml saline 
solution.
Trypsin stock: 1ml trypsin stock 
1ml EDTA stock
1ml bicarbonate stock in 100ml saline 
solution.
Carboxymethyl Cellulose (CMC): Sigma
CMC for overlay: 3.2g CMC in 100ml PBS 
2ml pencillin and streptomycin 
2ml fungizone 
8ml FCS
10ml bicarbonate stock in a final volume 
of 220ml MEM
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Methyl Violet Stain:
2.1.2 Histological Reagents 
Formol-saline
Albumin Preparation
Gallocyanin Stain
2.5g methyl violet stain, 100ml ethanol, in 
a final volume of 500ml distilled water
40% (v/v) formaldehyde (Sigma), 9 g sodium 
chloride [BDH] made up to 100ml with distilled 
water
Glycerin (Sigma) was added 1:1 to a liquid egg 
white and filtered through muslin.
5g Chromic potassium sulphate, 150mg 
gallocyanin in a final volume of 1200ml distilled 
water.
2.1.3 Virus Strains 
LO-1 rMu901:
JL fMSDl Vaccine Bulk:
JL (SKB) Vaccine Bulk:
Urabe Vaccine Bulk:
Mumps virus wild type strain. Isolated from a male child in 
1988 exhibiting symptoms of parotitis. The virus was isolated 
from the saliva sample on Vero cells at NIBSC.
Mumps vaccine bulk of the Jeryl Lynn strain was obtained from 
Merck Sharpe and Dohme. The vaccine has been shown to 
contain two distinct variants designated JL2 and JL5.
Mumps vaccine bulk of the Jeryl Lynn strain was obtained from 
SmithKline Beecham. The seed stock component of this 
vaccine was derived from the JL5 component of the mixed 
MSD JL vaccine.
Mumps vaccine bulk of the Urabe strain was obtained from 
SmithKline Beecham.
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Lo4/2:
m il:
JL2/4:
JL5/4:
Clinical Material 
99-0333
Clinical Material 
99-0333P1/V
A post-vaccine strain that was isolated from a vaccine recipient who 
had received the Urabe vaccine but who did not exhibit any 
symptoms. The isolate has been passaged twice on the Vero cell line.
A post-vaccine strain that was isolated from a Urabe MMR vaccine 
recipient who developed aseptic meningitis. This isolate has been 
passaged twice on Vero cells.
A sub-component of the JL MSD vaccine that was plaque purified in 
1990. This sample was subsequently passaged on Vero cells four 
times.
A sub-component of the JL MSD vaccine that was plaque purified in 
1990. This sample was subsequently passaged on Vero cells four 
times.
A wild-type strain of mumps virus. This is unpassaged clinical 
material, saliva, that was originally derived from a 9 year old female 
with symptomatic mumps.
This sample was produced by passaging the above specimen, 
99-0333, once on Vero cells.
2.2 Virus Propagation
Viruses were propagated using the following technique:
Growth medium was aspirated from a 25cm  ^ tissue culture flask containing an 80% 
confluent cell monolayer of Vero cells (approximately 5x10® cells) and the appropriate 
dilution of the virus inoculum, in maintenance medium, was added. The dilution of virus 
inoculum used was initially 3logio TCIDso/ml of virus, giving an approximate multiplicity of 
infection (MOI) of 0.0002 (1 TCID50 per 5000 cells). The cells were incubated with virus for
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approximately 2 hours in a humidified incubator at 35°C, 5% CO2, after which the inoculum 
was aspirated and fresh maintenance medium added. The infected cells were incubated at 
35°C, 5% CO2 until 80% CPE was observed. If no CPE was observed then the infected cell 
sheets were harvested 10 days post infection.
Virus was harvested by freezing the tissue culture flask containing infected cells at -70°C 
and thawing at room temperature to release any cell bound virus. The cell debris was 
removed from the virus by centrifugation at 1600 x g for 10 minutes at 25°C. The 
supernatant fluid, containing virus, was aliquoted and stored at -70°C.
2.3 Inocula Titration and Virus Titres
The virus inocula to titrated were done so in an Infectivity Assay in order determine viral 
titres.
2.3.1 Infectivity Assays
Infectivity assays were used in order to determine the titre of virus in a given sample. This 
was achieved by using various dilutions of the sample to infect cells in a 24 well plate and 
counting the number of plaques after a 7 day incubation period, assuming that one plaque is 
equivalent to one infectious virus particle.
Log dilutions of the viruses were made in MEM (Section 2.1) and 50pl volumes were added 
in duplicate to a 24 well plate. A Vero cell suspension was prepared in 40ml MEM (Section 
2.1) from one lOOcm  ^flask. One millilitre of the cell suspension was added to each well and 
incubated at 35°C in 5% CO2 for three hours. All the medium was removed and 1ml of 
carboxymethyl cellulose (CMC) [Section 2.1]) medium was added to each well. The plates 
were then incubated at 35°C in 5% CO2 for one week. The CMC layer was removed by 
suction pipetting into chloros. The cell sheet was washed with PBS and stained for 30 
minutes with 0.5% methyl violet stain in 20% ethanol.
2.3.2 Infectivity Assay Analysis
The assay plates were placed underneath a lighted magnifying glass. The dilution of the
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virus which produced between 50-200 plaques per well was chosen to be counted in order 
to reduce any error that may occur due to the counting of overcrowded plaques. After the 
number of plaques had been counted and recorded, the number of plaques in 1ml of the 
original inoculum was worked out by the calculation below.
Calculation: N x DF
______  X 1000
TV
Where
N = Number of plaques counted 
DF = Dilution factor
TV = Volume of virus solution in each well (pi)
This calculation gives the amount of virus in pfu/ml of the stock sample.
2.4 Rat Inoculation
After determination of the viral titres, pregnant Lewis rats were purchased to arrive at 
NIBSC during days 15-17 of the gestation period. The viruses to be inoculated were thawed 
and diluted to a concentration of 400 pfu/ml in MEM. Each virus strain was inoculated into a 
single litter of newborn pups, not older than 24 hours. For this a single pup was placed in a 
biosafety cabinet on several layers of paper towels. Five hundred micro-litres of the viral 
inocula was drawn up into a 2ml syringe and a 27G needle was attached. The pup was 
grasped firmly behind the head with the thumb and forefinger of one hand. Using the other 
hand, the needle was inserted through the left parietal area of the skull approximately 1- 
2mm left of the midline and approximately 2-3mm caudal to an imaginary line drawn 
midway between eyes and the ears. Figure 2.1.
The needle penetrated into the brain no more than 3mm below the outside surface of the 
head, and approximately 25pl of inocula (100 pfu of virus) was slowly injected. The 
inoculated pup was returned to its cage before any other pups were inoculated. The same 
syringe and needle were used to inoculate all the pups in the same litter. Once a litter of
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pups had been inoculated, the syringe, needle and paper towels were discarded and 
replaced, gloves were changed and the next litter to be inoculated was placed in the 
biosafety cabinet.
The rats were observed daily throughout the 30 day duration of the experiment for any 
abnormalities such as CNS abnormalities, severe motor abnormalities, inability to access 
water and food and wasting disease, as well as any pain or distress.
2.5 Extraction of Tissue
Rats to be euthanised were placed in a sealed container and exposed to carbon dioxide 
(CO2). After death, the rats were decapitated with a large pair of scissors by cutting at the 
base of the skull through the brain stem. The skin was removed from the head and, using a 
rongeurs, the upper part of the skull removed in order to expose the whole brain. The brain 
was removed from the skull by gently prying it from the calvarium with a closed pair of fine 
forceps. The brain was placed immediately in 10% formalin solution and fixed at 4°C for 1-2 
weeks.
2.6 Histology
Classic histological techniques, described below, were used to identify microscopic changes 
in tissue samples.
2.6.1 Cassette Labelling
Yellow plastic histology cassettes (R A Lamb) were mounted into an RA Lamb Cassette 
MicroWriter Machine. Using the MWC computer programme, the cassettes were labelled with 
the corresponding animal numbers (M02) which were logged in the Miscellaneous Histology 
Book. These were placed in order ready to be used.
2.6.2 Dissecting brain samples
Whole brain tissue samples were removed from the formol-saline and placed on a dissection 
board. Using a disposable eight inch trimming knife (RA Lamb), the brain was cut into two 
by cutting down the centre of the brain.
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Sites of 
injections. 0
template  
Coronal suture
3 cm
Sagitta l  suture
Figure 2.1: Location of the Inoculation Site. Showing the desired location of the needle for 
injection of the MuV into the neo-natal rat brain
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The central part of the brain was removed and replaced in the formol-saline container. The 
remaining left and right hand side of the brains are trimmed as shown in Figure 2.2, cuts 3 
and 4. The tissue was placed with the side closest to the centre of the brain down in the 
previously marked cassettes (Section 2.7.1). A plastic lid (R A Lamb) was secured onto the 
cassette and placed in a large plastic box containing formol-saline where it remained until 
the brain samples were ready for processing.
2.6.3 Processing of Brain Samples
The tissue samples were placed in a Leica TP 1050 Tissue Processor and run on a 
neurovirulence cycle with the following features as described in Table 2.1.
2.6.4 Sample Blocking
The samples were removed from the Leica TP 1050 Tissue Processing Machine and placed 
immediately into the molten paraffin wax hold of the wax dispenser (RA Lamb Blockmaster 
III). The lid from a cassette in the molten paraffin wax was removed carefully. The sample 
was removed from the cassette and placed in a small metal sample tray containing a layer 
of molten wax. This was then placed on the small metal freezing plate of the Blockmaster I I I  
and frozen so that the sample remained in place. The yellow plastic cassette, with M02 
number, was placed over the small metal sample tray and filled with molten wax. The metal 
tray was placed on the large freezing plate to set. This was repeated for all samples. Once 
they had set, the metal trays were removed by snapping them off. The embedded samples 
were sorted according to their numbers ready for sectioning.
2.6.5 Slide Labelling and Preparation
Menzel Superfrosted Slides were labelled with the corresponding cassette number using an 
RA Lamb MicroWriter. Slides were stacked into the entry port and using the MWC computer 
programme, sample numbers were etched onto the slides in duplicate. To aid sample 
adherence to the slide a preparation of albumin was spread over the slides using a finger.
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Table 2.1: Neurovirulence cycle for processing of rat brain tissue.
Reagent Time (hours) Temperature C
Formalin 00.05 Ambient
Industrial Methylated Spirits 
(IMS) 50% Concentration
01.00 Ambient
IMS (70%) 01.00 Ambient
IMS (95%) 01.00 Ambient
IMS (100%) 01.00 Ambient
IMS (100%) 01.00 Ambient
IMS (100%) 01.00 Ambient
Ethanol (50%) Xylene 
(50%)
02.00 Ambient
Xylene 02.00 Ambient
Xylene 02.00 Ambient
Paraffin Wax 02.00 60
Paraffin Wax 02.00 60
Paraffin Wax 02.00 60
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2.6.6 Microtomy
Brain samples were placed in a Leica RM2135 Microtome set at 20pm trimming thickness. 
Excess wax was trimmed from the embedded tissue until the sample was reached. The 
sample block was removed and placed sample down in a layer of Mollifex (BioRad) for 20 
minutes in order to soften the tissue for cutting. Once softened, the blocks were re-mounted 
onto the microtome set at 12pm cutting thickness. Once two or three sample slices had 
been obtained, they were floated on water in a water bath set at 42°C in order to flatten the 
samples and remove creases.
Once the samples were flat, slides were immersed in the water beneath the floating sections 
and removed carefully onto the slide. These slides were then placed in a 36°C oven to dry. 
The paraffin wax blocks were stored in large metal storage tray containers where they can 
be kept indefinitely.
2.6.7 Staining
Once the slides had been allowed to dry, at least overnight, they were de-waxed. The slides 
were placed in Xylene (BDH) for 5 minutes, removed and placed in a fresh container of 
xylene for 5 minutes. This was repeated until visible examination revealed that all wax had 
been removed. The slides were then dipped in Celloidin, washed with distilled water, placed 
in a Gallocyanin stain container and incubated at 56°C for 3 hours, after which the slides 
were removed and washed gently in distilled water. The slides were then placed in 
increasing concentrations of ethanol every five minutes starting with 70%, 90%, then 
100%. After the final 100% ethanol soak, the slides were placed in xylene for 5 minutes and 
then re-placed in another container of xylene. Individual slides were taken from the xylene 
and placed face down on blotting paper whilst the back was dried with a white Wypall. The 
slides were turned over and using a plastic Pasteur pipette, two large spots of DPX (Sigma) 
were placed on the sample which were then covered with a glass coverslip making sure that 
the DPX was spread completely over the sample and that no bubbles appeared. If  bubbles 
appeared, they were removed by gently pressing the coverslip to move the bubbles to the
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edge of the slide. The slide was then left to dry overnight to secure the coverslip to the 
slide. Once dried, any leaked dry DPX was removed from around the coverslip carefully 
using a scalpel blade. The slide was then ready for microscopic examination.
2.7 Microscopy
Once the slides had been prepared, as in the previous section, they were arranged 
according to their M02 number in slide sample holders ready for microscopic examination 
with a Zeiss microscope at a magnification of xlOO.
2.7.1 The Cerebral Cortex
The cerebral cortex is located above the horse-shoe shaped hippocampus. Using a graticule 
placed in the microscope lens, the width of the cerebral cortex from the top of the 
hippocampus to the edge of the cortex was measured, as shown in Figure 2.2. This 
measurement was recorded for each slide.
2.7.2 The Third Ventricle
The third ventricle is located at the lower edge of the dorsal horse-shoe (Ammon's horn) of 
the hippocampus (Figure2.3). First, the ventricular ependyma was analysed for any evidence 
of cellular migration or roughness. Then the sub-ependyma was analysed for evidence of 
oedema surrounding the ventricle. Lastly the size of the third ventricle was measured using 
a graticule as shown in Figure 2.3 and noted. Also, a grading on the size of the third 
ventricle was made by eye examination and recorded along with the graticule 
measurement.
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Figure 2.2: Cerebral Cortex. The arrow details the measurements taken into consideration 
when scoring the cerebral cortex.
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Figure 2.3: Third ventricle. The arrow details the area of the third ventricle taken in to 
consideration when scoring.
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2.7.3 The Lateral Ventricle
The lateral ventricle is located at the upper edge of the dentate gyrus of the hippocampus 
(Figure 2.4). First, the ventricular ependyma was analysed for any evidence of cellular 
migration or roughness. Then the sub-ependyma was analysed for evidence of oedema 
surrounding the ventricle. Lastly the size of the lateral ventricle was measured using a 
graticule as shown in Figure 2.4 and noted. In addition, a grading on the size of the lateral 
ventricle was made by eye examination and recorded along with the graticule measurement.
2.7.4 The Cerebellum
The cerebellum is a highly folded structure as can be seen in Figure 2.5. There are three 
layers to the cerebellum, the external molecular layer, the Purkinje cell layer and the internal 
granular layer (Figure 2.65on the extent of visible damage.
2.7.5 Slide storage
Once the slides had been read, they were stored in metal slide storage cabinets at room 
temperature, where they can be stored.
66
%w
^ M P
*:fsK4
Figure 2.4: The Location of the Lateral ventricle. The arrow details the area of the lateral 
ventricle taken in to consideration when scoring.
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Figure 2.5: The cerebellum: defining the three layers. The arrows show the three layers of 
the cerebellum.
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2.8 FDA Scoring Method
This method only takes in to consideration the size of the lateral ventricle in relation to the 
rest of the brain.
A grid of squares measuring 1mm by 1mm was placed over a neo-natal rat brain exhibiting 
hydrocephalus. The number of squares that the lateral ventricle encompassed was 
measured and noted (a). The number of squares the whole of the brain (excluding the brain 
stem) was also measured (b). (a) was then divided by (b) and the resulting figured 
multiplied by 100 to give the percentage area the lateral ventricle occupies of the whole 
brain. This percentage was then noted.
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3 Results
3.1 Introduction
To assess and validate the neo-natal rat as a model for mumps neurovirulence, newborn 
rats were inoculated i.c with wild-type and vaccine strains of mumps virus and assessed by 
histopathological grading often areas of the brain as follows:
Cerebral Cortex Thickness
Third Ventricle: Epithelial Lining
Sub-epithelial Area 
Size
Lateral Ventricle: Epithelial Lining
Sub-epithelial Area 
Size
Cerebellum: Molecular Layer
Purkinje Cell Layer 
Granular Layer
Rubin et al (1998a) have demonstrated that variation in the size of the lateral ventricle 
could be indicative of the neurovirulent activity of mumps virus in a neonatal rat brain. 
Infection by MuV of the ventricular ependyma alters the equilibrium flow of cerebrospinal 
fluid (CSF) into the ventricular space, increasing the size of the ventricle. For this reason, 
the variation in the size of the lateral ventricle area of the brain has been proposed as a 
suitable marker to determine the levels of neurovirulence that may be associated with a 
particular strain or vaccine preparation.
In addition to the ventricle size other parameters, listed above, were also assessed during 
this study in order to identify what other areas of the brain were affected following I.C 
inoculation of mumps virus. If altered following inoculation they could provide additional 
histopathological markers for the assessment of mumps virus neurovirulence.
It has been noted in poliovirus neurovirulence studies of macaques, undertaken at NIBSC,
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that the thickness of the cerebral cortex alters with the degree of neurovirulence. 
Observations made during this project propose that a decrease in the thickness of the 
cerebral cortex is a direct result of an increase in the size of the lateral ventricle, Appendix 
II. Rubin et al (1998) noted that an increase in size of the third ventricle accompanied the 
increase in size of the lateral ventricle; however, it was observed that the third ventricle size 
increase was not as significantly large as the lateral ventricle increase. As MuV infects the 
cell lining of the ventricular space, it was thought probable that there might be some 
detectable changes in cellular morphology and distribution. The molecular, purkinje and 
granular layers of the cerebellum were also considered as suitable areas for measuring the 
neurovirulent activity of MuV, as Rubin et al (1998) described the occurrence of cellular 
migration in MuV infected neo-natal rat brain samples.
By studying the parameters listed above, the usefulness of the neo-natal rat to detect 
neurovirulence of mumps virus strains would be established.
In each RNVT, samples were designated a number or letter for identification. The list of 
viruses inoculated and the number of animals used in each RNVT is shown in Table 3.1. The 
complete histopathological data of each animal for all RNVT are tabulated in Appendix 1.
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Table 3.1 : List of RNVT with viruses and number of animal inoculated.
RNVT Mumos Viruses Used Desianation No of 
Animals
B Lol/Mu90 Wild Type 1 10
SKB JL Vaccine Bulk 2 8
SKB Urabe Bulk Vaccine 3 19
Clinical Material 10 4
Clinical Material IV 11 4
D Lol/Mu90 Wild Type 1 10
SKB JL Vaccine Bulk 2 11
Nt5 Urabe Virus 7 18
FDAC C 22
E Lol/Mu90 Wild Type 1 10
SKB JL Vaccine Bulk 2 10
MSD JL Vaccine Bulk 4 18
FDAD D 21
F Lol/Mu90 Wild Type 1 12
SKB JL Vaccine Bulk 2 10
Lo4/2 Urabe Virus 6 20
FDA A A 19
G Lol/Mu90 Wild Type 1 10
SKB JL Vaccine Bulk 2 9
JL2/4 Sub-species 8 19
JL5/4 Sub-species 9 19
H Lol/Mu90 Wild Type 1 10
SKB JL Vaccine Bulk 2 11
FDAE E 20
I Lol/Mu90 Wild Type 1 11
SKB JL Vaccine Bulk 2 11
FDAB B 23
J Lol/Mu90 Wild Type 1 9
SKB JL Vaccine Bulk 2 9
Diluent 5 19
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3.2 Histological Grading Procedures.
The grading method used at NIBSC is based on a visual evaluation of the specified 
parameters. These were classified into a grading, as below, depending on the severity of the 
change.
Table 3.2 : Summary of the grading system used by NIBSC
Grading Severity
Negative (-) No difference from the control
Low-Level (-/+) Marginal increase in lateral ventricle size 
from the control.
One (+) Mild. Noticeable increase in lateral 
ventricle size.
Two (++) Moderate. Increase in size of lateral 
ventricle.
Three (+++ ) Severe. Lateral ventricle covers a large 
part of the brain.
Four (+ ++ +) Overwhelming. Lateral ventricle covers 
most of the brain.
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3.2.1 Negative Grading
Animals inoculated with the sample diluent (ie: MEM only) did not show any increase in the 
lateral and third ventricles (Figure 3.1A). The cerebral cortex showed no alteration in its 
thickness (Figure 3.IB). The epithelial layers of each ventricle were smooth and showed no 
evidence of cell migration or surrounding oedema (Figure 3.1C and D). No cellular migration 
or clumping occurred in the layers of the cerebellum (Figure 3. IE).
3.2.2 -/+  grading
Animals displaying a low-level affect showed a small visible increase in the size of the lateral 
ventricle, whilst the third ventricle showed no increase in size (Figure 3.2A). There was no 
evident decrease in the thickness of the cerebral cortex (Figure 3.2B). The ventricular 
epithelium gave a slight roughened appearance though no oedema was visible (Figure 3.2C 
and D). The cerebellum showed no evidence of cellular migration within any of the three 
layers (Figure 3.2d).
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Figure 3.1: Examples of sections of the brains of animals inoculated with the diluent.
Showing the third and lateral ventricle sizes (A), the cerebral cortex thickness (B), the 
epithelial and sub-epithelial layer of the lateral ventricle (c), the epithelial and sub-epithelial 
layers of the third ventricle (D) and the three layers of the cerebellum (E)
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Figure 3.2: Examples of sections of the brains of animals showing a typical low-level 
effect. Showing a small increase in the size of the lateral ventricle and no increase in the 
third ventricle (A), a decrease in the thickness of the cerebral cortex (B), the epithelial and 
sub-epithelial layers of the lateral ventricle (C), the epithelial and sub-epithelial layers of the 
third ventricle (D) and the three layers of the cerebellum (E).
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3.2.3 Grade One (+)
In animals displaying a Grade One effect, the laterai and third ventricles showed an increase 
in size in comparison to the negative control group (Figure 3.3A). The thickness of the 
cerebral cortex decreased (Figure 3.3B), and the ventricular epithelial lining showed 
roughened edges and cellular migration, with surrounding oedema (Figure 3.3C and D). The 
cerebellum molecular layer showed cell migration towards the centre of the layer, with the 
remaining two iayers being unaffected (Figure 3.3E).
3.2.4 Grade Two (++)
In neo-natal rat brains displaying Grade Two activity, the lateral and third ventricles were 
observed to have increased in size, compared to a Grade One neuroviruient activity (Figure 
3.4A). The ventricular epithelial of the third ventricle showed an increase in cell migration 
though no sample showed any evidence of oedema at Grade Two (Figure 3.4C). The lateral 
ventricle showed an increased level of cellular migration and oedema surrounding the 
ventricle. The cerebral cortex displayed a marked decrease in thickness (Figure 3.4B), and 
the molecular layer of the cerebellum showed evident migration of cells towards the centre 
of the layer with noticeable clumping (Figure 3.4D).
Occasionally, a sample shows evidence of activity which cannot be umabiguously classified 
either as a Grade One or Two but may fall between two grades. Such samples were graded 
as (+ /+ + ). This was more common for the increase in size of the lateral ventricle as shown 
above, but was occasionally also observed in other areas, such as the thickness of the 
cerebral cortex, the lateral ventricular epithelial and sub-epithelial layers.
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Figure 3.3: Examples of sections of the brains of animals showing a typical Grade 
One effect. Showing an increase in the size of the lateral ventricle (a), the decrease In the 
cerebral cortex thickness (B), the epithelial and sub-epithelia layers of the lateral ventricle 
(C), the epithelial and sub-epithelial layer of the third ventricle (D), and the three layers of 
the cerebellum (E)
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Figure 3.4 : Examples of sections of the brains of animals showing a typical Grade 
Two effect. Showing an increase in the size of the lateral and third ventricle (A), a decrease 
in the cerebral cortex thickness (B), the epithelial and sub-epithelial layer of the third 
ventricle (C), the epithelial layer of the lateral ventricle (D), and the three layers of the 
cerebellum (E)
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3.2.5 Grade Three (+ ++ )
Rat brains which displayed a Grade Three effect showed an increase in size of the lateral 
and third ventricles in comparison to Grade Two (Figure 3.5A). The cerebral cortex showed 
a decrease in size in comparison to Figure 3.4 (Figure 3.5B). There was no histopathological 
evidence of epithelial or sub-epithelial changes of Grade Three activity for the lateral and 
third ventricle. The cerebellum showed an increase in cellular migration and clumping in the 
molecular layer in comparison to Grade Two, and there was also evidence of cellular 
bunching in the Purkinje cell layer. The granular layer showed no change (Figure 3.5 C and 
D). The specimens that showed higher activity than Grade Two but lower than Grade Three 
were classified as (4-+/-n-+); this was only found in the size of the lateral ventricle.
3.2.6 Grade Four (+ ++ +)
Of the few animals that displayed Grade Four activity, it was presented only in the size of 
the lateral ventricle, the thickness of the cerebral cortex and the cerebellum regions. The 
size of the lateral ventricle had increased markedly from a Grade Three scale (Figure 3.6A); 
the thickness of the cerebral cortex had also decreased markedly (Figure 3.6B). The 
clumping of cells in the molecular layer of the cerebellum was evidently increased (Figure 
3.6C), and the cells in the Purkinje layer had bunched and pinched off into the granular 
layer which showed evidence of oedema-like cellular damage (Figure 3.6D).
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Figure 3.5 : Examples of sections of the brains of animals showing a typical Grade 
Three effect. Showing an increase in the size of the lateral ventricle (A), a decrease in the 
size of the cerebral cortex (B) and the migration of the cells of the molecular layer of the 
cerebellum (C + D)
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Figure 3.6 : Examples of sections of the brains of animals showing a typical Grade Four 
effect. Showing an increase in the size of the lateral ventricle (A), a decrease in the 
thickness of the cerebral cortex (B), the clumping of cells in the molecular layer (C), and the 
clumping of purkinje cells in the granular layer (D).
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3.3 Control Viruses
In each of the eight RNVT's performed in this study, two strains of MuV were used as 
experimental controls. Lol/Mu90 was used as a positive neurovirulent control and SKB JL 
vaccine strain was used as a negative control. Lol/Mu90 MuV is a wild type strain which 
was isolated from an individual exhibiting parotitis. This virus has been used before in 
macaque studies undertaken at NIBSC which concluded that amongst the viruses tested the 
Lol/Mu90 was the most neurovirulent strain (Afzal et al 1999a). It was therefore selected to 
be used as a positive control in this study. The SKB JL MuV vaccine strain has not been 
reported to be associated with severe post-vaccination adverse events in recipients and was 
also used in macaque studies at NIBSC, in which this virus was found to have no 
neurovirulent effect.
Each RNVT experiment contained, in addition to the test samples, a positive control and a 
negative control. The cumulative data shown in Table 3.3 for these controls can be used to 
identify discrepancies between individual tests. The data show assay-to-assay variation 
between different RNVT's which were conducted at different times due to logistical and 
technological reasons. Based on the previous results of the monkey model, it was expected 
that SKB JL Vaccine Bulk inoculum would show no evidence of neurovirulence. Analysis of 
Table 3.3 reveals that in each test about 40-90% of animals inoculated with SKB JL 
preparation showed no signs of enlargement of the lateral ventricle. Most of the remaining 
animals could not be conclusively scored by the histopathological parameters applied as 
whether or not the virus had any effect and were, therefore, classified into the (-/+ ) grade. 
However, some animals in the RNVT D and I exhibited up to a Grade One (9% for D [2 
animals] and 18% for I [4 animals]), and Grade Two (9% for I [2 animals]) level effects 
contributing to a higher background scoring profile than other RNVTs.
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In the macaque neurovirulence model, the Lol/Mu90 strain scored higher compared to other 
strains evaluated. Analysis of the Lol/Mu90 strain by the RNVT (Table 3.3) shows differences 
between various tests. The assessment of this virus group spread mainly between Grade One 
and Grade Two amongst the difference RNVT's, and is therefore considered normal for this 
virus group. For RNVT B, grading for the positive control ranges from (-/+ ) to Grade Three, 
which is the widest range. Approximately 70% of the specimens of RNVT E are in the Grade 
Three to Grade Four range which is not reflected in the scoring of the positive control samples 
of other RNVT's. This relatively high scoring for Mu90 in this RNVT is not observed with animals 
that were inoculated with the negative control strain.
3.3.1 Control Parameters
Table 3.3 shows data generated for the size of the lateral ventricle of the positive and negative 
controls exclusively. The results of the other study parameters referred to in Section 3.1 are 
shown graphically in Figure 3.7 for the positive control Lol/Mu90 and in Figure 3.8 for the 
negative control JL SKB vaccine.
The collective data from all animals inoculated with the positive control preparation from each 
RNVT shows that the thickness of the cerebral cortex could be graded from Negative to Grade 
Two (Figure 3.7). The Third Ventricle data showed that 60-75% of animals scored negative 
with the remainder scoring up a to Grade One. Occasionally a grade higher than One was seen 
(Figure 3.7). The lateral ventricle was the most affected area of the brain with the majority of 
specimens showing Grade One level effects in each parameter assessed. The molecular layer of 
the cerebellum also showed a variety of grades from Negative to Grade Two/Three, again with 
most scoring at a Grade One (Figure 3.7). Both the Purkinje and Granular Cell Layers scored 
mainly negative, although the Purkinje cell layer had one specimen graded to a level three.
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Figure 3.7 : Grading assessment of the ten parameters of animals inoculated with the 
LOl/Mu90 strain.
Key: 1 Thickness of cerebral cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Lateral Ventricle; Size
8 Cerebellum; Molecular layer
9 Cerebellum; Purkinje cell layer
10 Cerebellum Granular layer
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Figure 3.8 : Grading assessment of the ten parameters of animals inoculated with SKB JL 
Vaccine strain.
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Lateral Ventricle; Size
8 Cerebellum; Molecular layer
9 Cerebellum; Purkinje cell layer
10 Cerebellum Granular layer
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The collective data of various parameters of animals inoculated with the negative control virus 
in various RNVT's show that the cerebral cortex remains unchanged in the majority of 
specimens, with only two specimens showing Grade one level effects (Figure 3.8). The virus 
exhibits no effects on the Third Ventricle. There was a small effect on the lateral ventricle. The 
epithelial layer showed slight signs of infection with one specimen scoring Grade One, as did 
the surrounding area, with four specimens of Grade One. The ventricle size increased in three 
specimens on average to Grade One and one specimen to Grade Two. Two specimens showed 
the virus having an effect on the molecular layer of the cerebellum to a Grade One, with the 
remainder of the specimens showing a negative or low-level effects (Figure 3.8). The Purkinje 
cell layer showed two specimens having a low-level effect with the Granular layer showing no 
effects.
Both Lol/Mu90 and SKB JL Vaccine Bulk support the observation that the lateral ventricle and 
the cerebellum appear to be the regions of the brain which are affected most following MuV I.C 
inoculation (Figure 3.8). The third ventricle exhibits some change in response to Lol/Mu90 but 
the change is less significant than the one demonstrated by the lateral ventricle, and therefore 
would appear to be a less suitable indicator of neurovirulence in the rat model. Similarly the 
cerebral cortex thickness shows a variety of responses and does not appear to be a reliable 
parameter for measuring the neurovirulence mumps virus strains.
3.3.2 Observations of Jeryl Lynn Mumps Vaccine Inoculated Animals 
For the purpose of this report, data presented for viruses under test are grouped together in 
relation to their genetic similarities and not according to the groupings used to conduct RNVT's 
(Appendix I). This section details the results of mumps viruses that were derived from the Jeryl 
Lynn vaccine strain (MSD). These viruses were studied in two different RNVT's i.e:
RNVT E - MSD JL Vaccine Bulk 
RNVT G - JL2/4 Sub-species 
RNVT G - JL5/4 Sub-species
88
Table 3.4: Grading assessment of the Lateral Ventricle size for the JL vaccine and Its associated 
derivatives.
Grading MSD JL
Vaccine
Bulk
Percentage of 
controls for RNVT 
E
JL2/4 Sub­
species
JL5/4 Sub­
species
Percentage of 
controls for RNVT G
+ - + -
- 100 0 40 63.1 5.3 0 55.5
■/+ 0 0 60 31.6 68.4 0 45.5
+ 0 0 0 5.3 10.5 40 0
+ /+ + 0 10 0 0 15.8 10 0
++ 0 10 0 0 0 40 0
+ + /+ + + 0 10 0 0 0 10 0
+ H—h 0 40 0 0 0 0 0
H—1—H+ 0 30 0 0 0 0 0
Average
%
100 100 100 100 100 100 100
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The MSD JL Vaccine Bulk virus had no effect on the size of the lateral ventricle. The SKB JL 
Vaccine Bulk virus, used as a negative control, appears to have more effect than the MSD JL 
Vaccine Bulk. The data of Lol/Mu90 strain. Table 3.3 and Figure 3.7, show that Grade One to 
Grade Two level effects were the normal effect of the positive control preparation. In RNVT E 
the higher assay background may be attributable to an anomaly in the slide reading or in the 
tissue processing (Tables 3.3 and 3.4). However, this is unlikely since the negative control 
results of this test did not score unusually high.
The JL2/4 vaccine sub-component virus does not exhibit a significant effect on the lateral 
ventricle in comparison to the negative control in RNVT G, although it did have one specimen 
scored in the Grade One group.
The JL5/4 vaccine sub-component virus exhibits more effect on the lateral ventricle in 
comparison to the negative control. Only one specimen showed no effect, with a large majority 
of specimens exhibited relatively low-level effects. Two specimens had Grade One and three 
specimens had Grade Two level effects. In comparison to the negative control, the JL5/4 
vaccine sub-variant had a more enlarging effect on the lateral ventricle.
The scoring results of animals inoculated with positive control virus in RNVT E and RNVT G 
showed a majority of specimens were graded between Grade One and Two, whereas the 
animals inoculated with the negative control virus were mostly divided between negative and -  
/-^ groups, in line with the distribution seen in Table 3.3 and Figure 3.8.
There is a difference in the neurovirulence of the two virus sub-components of the MSD JL 
Vaccine Bulk, as 5.3% specimens of animals inoculated with JL5/4 were found to be completely 
negative compared to 63.1% of animals inoculated with JL2/4. However MSD JL Vaccine Bulk 
virus had no effect on the lateral ventricle as all specimens were negative.
In relation to other parameters discussed in section 3.1.1, the MSD JL Vaccine Bulk inoculated 
animals show a low-level, i.e -/+ , effect on the thickness of the cerebral cortex seen in 2 
specimens and the sub-epithelial layer of the third ventricle, as seen in 1 specimen in Figure 3.9
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Figure 3.9 : Grading assessment of the nine additional parameters of animals inoculated with 
MSD JL
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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This differs from the negative control group which graded completely negative. The positive 
control inoculated animals graded between Grade One and Grade Two (Figure 3.7). Parameters 
2, 4, and 5 were found to be similar to the negative control group, well within the expected 
ranges (Figure 3.8 and Appendix I).
Parameter 6 shows four specimens having low-level effects and one specimen having Grade 
One level effects. The JL MSD Vaccine Bulk inoculated animals had no effects on the sub- 
epithelial layer of the lateral ventricle. Of the cerebellum, JL MSD Vaccine Bulk had a low-level 
effect on the molecular layer, 55% or 11 specimens. The negative control for RNVT E also 
showed that SKB JL Vaccine Bulk virus had some effects on the molecular layer, as 22.2% or 
two specimens had low-level effects and 22.2% or two specimens had Grade One effects. The 
JL MSD Vaccine Bulk virus did not show any effects on the other layers of the cerebellum, 
whereas the negative control had one specimen showing a low-level -/+  effect on the Purkinje 
Cell Layer.
The JL2/4 sub-component virus showed low-level effects on the epithelial layer and size of 
the third ventricle. Figure 3.10. The negative control virus in RNVT G showed no effect. The 
animals inoculated with the negative control virus displayed evidence of the lateral ventricle 
being affected, as did the animals inoculated with the JL2/4 sub-component vaccine virus. The 
effect in both cases is low-level, -/+  grade. The negative control virus exhibited 11.1%, or one 
animal, showing effects on the molecular layer of the cerebellum, whereas the vaccine virus 
showed 33.3%, or three specimens, to be affected. Neither had any effects on the remaining 
parameters of the cerebellum.
The thickness of the cerebral cortex of JL5/4 sub-component vaccine virus inoculated animals 
exhibited a range of scoring grades. Like the negative control animals it showed a high degree 
of negative grading, with few specimens showing Grade One and Grade Two level effects 
(Appendix II). Animals inoculated with the positive control virus showed Grade One and Two 
level effects. The JL5/4 sub-component virus had a relatively low-level effect on the epithelial
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Figure 3.10 : Grading assessment of the nine additional parameters of animals inoculated with 
JL2/4
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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Figure 3.11 : Grading assessment of the nine additional parameters of animals inoculated with 
JL5/4
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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layer and size of the third ventricle, as did the JL2/4 sub-component. The JL5/4 component 
virus produced effects on the lateral ventricle which were more severe than the effects seen 
with negative control and JL2/4 virus preparations. Like the positive control virus, the JL5/4 
variant had Grade One effects on the epithelial layer of the lateral ventricle. Animals inoculated 
with the positive control scored in the One/Two and Two grades, whereas the animals 
inoculated with JL5/4 preparation scored mainly in the negative and low-level groupings. The 
sub-epithelial changes seen in animals inoculated with JL5/4 and positive control preparation 
were of Grade One and Two levels in some animals.
The effect on the molecular layer of the cerebellum was similar in animals inoculated with the 
positive control and JL5/4 sub-variant vaccine virus.
3.3.3 Observations of Urabe Mumps Vaccine Inoculated Animals.
This section details the results of the Urabe vaccine and its associated isolates that were 
analysed in the following three RNVT's:
RNVT B - SKB Urabe Vaccine Bulk 
RNVT F - Lo4/2 Urabe Post-vaccine isolate 
RNVT D - Nt5 Urabe Post-vaccine Isolate
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Table 3.5: Grading assessment of the Lateral Ventricle size of Urabe vaccine and associated 
derivatives.
Grading SKB Urabe
Vaccine
Bulk
Percentage 
of Controls 
for RNVT B
Lo4
Urabe
Post-
Vaccine
Isolate.
Percentage 
of Controls 
For RNVT F
Nt5
Urabe
Post-
Vaccine
Isolate.
Percentage 
of Controls 
for RNVT D
+ - + - + -
- 21 0 50 30 0 60 16.7 0 54.5
-/+ 42.1 10 37.5 60 8.3 40 44.4 10 36.4
+ 26.3 30 12.5 10 33.3 0 27.8 60 9
+ /+ + 5.3 20 0 0 16.7 0 5.5 10 0
++ 5.3 20 0 0 41.7 0 5.5 20 0
+ + /+ + + 0 10 0 0 0 0 0 0 0
+++ 0 10 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100
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The SKB Urabe Vaccine Bulk virus had a range of effects on the size of the lateral ventricle, 
with 21% of animals scoring negative. The vaccine virus displayed a Grade One level enlarging 
effect in 26.3% or five specimens Grade One or higher in 5.3% of animals and Grade Two level 
in another 5.3% of animals (Table 3.5). The pattern of histological scoring for the negative 
control was in line with the pattern seen in other RNVT's. The positive control virus used in 
RNVT B produced effects of Grades One to Three (Table 3.5).
The Lo4 Urabe virus displayed Grade One level effects in 10% of animals with the remainder 
showing no effects or that of a low-level score., essentially identical to the negative control 
(Table 3.5). The positive control virus showed a majority scoring between Grade One and 
Grade Two, 91.7%, which is consistent with the pattern of the positive control preparation in 
other RNVT's (Table 3.3). Animals inoculated with the Nt5 Urabe virus showed a range of 
grades similar to the animals that were inoculated with the SKB Urabe Vaccine Bulk material. 
The negative control virus of RNVT D graded similar to RNVT B. The positive control virus of 
RNVT D showed that the majority of specimens (90%) had a Grade One to Two level effect, 
which is also consistent with the results of positive control samples examined in other RNVT's. 
The relatively high scoring profile seen with SKB Urabe Vaccine virus and Nt5 Urabe isolate 
inoculated animals could possibly be due to the high assay backgrounds as the negative control 
virus used in RNVT B and D scored slightly higher than it's normal pattern seen in other RNVT's 
(Table 3.3).
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Figure 3.12 : Grading assessment of the nine additional parameters of animals inoculated with 
SKB Urabe Vaccine
Key: 1 Thickness of the Cerebral Cortex
10 Third Ventricle ; Epithelial changes
11 Third Ventricle ; Sub-epithelial changes
12 Third Ventricle ; Size
13 Lateral Ventricle ; Epithelial changes
14 Lateral Ventricle; Sub-epithelial changes
15 Cerebellum; Molecular layer
16 Cerebellum; Purkinje cell layer
17 Cerebellum Granular layer
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In relation to other parameters discussed in section 3.1.1, the SKB Urabe virus inoculated 
animals had one specimen which showed an enlarging effect on the thickness of the cerebral 
cortex, the negative control group also had one specimen of a similar nature (Table 3.3 and 
Figure 3.8). The positive control group animals had a majority of specimens belonging to the 
Grade One level effects. Both the negative and positive control group animals exhibited no 
effects on the third ventricle, whereas the SKB Urabe Vaccine virus inoculated animals showed 
low-level effects on all parameters and Grade One level effects on the epithelial and sub- 
epithelial layers (Table 3.3, Figures 3.7 and 3.8). Four specimens (21.2%) showed Grade One 
effects on the epithelial layer and three specimens (15.9%) showed Grade One level effects on 
the sub-epithelial layer. Both the positive and negative control group animals showed effects on 
the sub-epithelial layer of the lateral ventricle similar to the levels seen with SKB Urabe vaccine 
virus inoculated animals. The positive control group animals had more severe effects on the 
epithelial and sub-epithelial layers than the animals inoculated with the negative control and 
vaccine viruses (Table 3.3, Figures 3.7 and 3.8). The negative control virus had no effects on 
the epithelial layer whereas the SKB Urabe Vaccine virus inoculated animals had one specimen 
showing Grade One/Two level effects, and 5 specimens (26.5%) showing Grade One level 
effects (Tables 3.3 and 3.5, Appendix I). The negative control virus inoculated animals showed 
that three specimens, (37.5%) had Grade One level effects. The vaccine virus showed that 3 
specimens (16.6%) had Grade One/Two level effects and the same number had Grade One 
level effects. The SKB Urabe vaccine virus inoculated rats showed effects similar to the animals 
inoculated with the positive control virus (RNVT B) than the animals inoculated with the 
negative control virus for variations in the molecular layer of the cerebellum (Table 3.5). The 
Purkinje cell layer of the SKB Urabe inoculated specimens displayed mainly negative to low-level 
effects, one specimen had a Grade One level effect. The animals inoculated with the negative 
control virus gave grades that were negative for all parameters of the cerebellum (Appendix I).
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Figure 3.13 : Grading assessment of the nine additional parameters of animals inoculated with 
Lo4 Urabe Sample
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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Animals inoculated with the Lo4 Urabe virus showed no effects on the thickness of the cerebral 
cortex or the third ventricle (Appendix I). The animals inoculated with the negative control virus 
also had no effects on these parameters. The positive control virus had either negative or low- 
level effects on these parameters. One animal had low-level effects on the epithelial layer of the 
lateral ventricle (Appendix I). Specimens derived from the positive control virus inoculated 
animals showed effects on the epithelial layer of Grade One. Of the animals inoculated with Lo4 
virus, one animal exhibited Grade One level effects on the sub-epithelial layer, the same was 
observed in animals inoculated with the negative control virus (Appendix I). The animals 
injected with positive control virus had effects of the Grade One and Two levels. There were 
some low-level effects (16.6%, 2 specimens) in the molecular layer of the cerebellum in Lo4 
inoculated animals. The negative control group for this parameter was completely negative 
while the positive control group had Grade One level effects in some animals. The Purkinje and 
Granular Cell Layers both remained unaffected in the negative control and Lo4 inoculated 
Groups (Appendix I).
The thickness of the cerebral cortex showed variation between negative control group animals, 
and those inoculated with Nt5 in RNVT D (Appendix I). The Nt5 virus inoculated animals had 
majority of specimens that were negative, one specimen that had low-level effects and two 
specimens that had Grade One level effects. The Nt5 virus had negative to low-level effects on 
the third ventricle (Appendix I). The negative control group displayed mainly negative to low- 
level effects on the epithelial changes of the lateral ventricle whilst two specimens had some 
measurable effects. The positive control virus showed that the majority of animals had low-level 
effects on the sub-epithelial part of the lateral ventricle, and only two specimens had Grade 
One level effects (Appendix I). The negative control group had four specimens that showed 
low-level effects, whereas the Nt5 inoculated group showed low-level effects on the sub- 
epithelial layer and two specimens having Grade One level effects. The negative control group
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Figure 3.14 : Grading assessment of the nine additional parameters of animals inoculated with 
Nt5 Urabe Sample
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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displayed low-level effects on both the molecular and purkinje cell layer of the cerebellum, 
scoring two specimens in the former and one specimen in the latter category (Appendix I). The 
animals inoculated with the positive control virus showed low-level to Grade One level effects 
on the molecular layer but not on the Purkinje cell layer. The Nt5 virus had low-level effects on 
both layers, five specimens in the former and four specimens in the latter. None of the viruses 
of the Urabe vaccine virus related group had any effects on the Granular Cell layer (Appendix
I).
3.3.4 Observations of Clinical Material Inoculated Animals
This section details the histopathological results of animals that were inoculated with mumps 
specific unpassaged clinical material, and limitedly passaged, clinical material designated 99- 
0333 and 99-0333V, respectively.
Animals inoculated with the clinical material, 99-0333, showed variations in size of the ventricle 
region of the brain compared to animals inoculated with the negative control virus preparation 
(Table 3.6). One animal (25%) of the 99-0333 group showed Grade one/two effects. The same 
was observed for the animals that were given Vero cell passaged version of the clinical material 
99-0333V. The performance of the negative control in RNVT B was in line with the 
performances of this material observed in other RNVT's (Table 3.3). The Grade one level effects 
seen with the negative control material have also been observed in RNVTs D and I  .The 
distribution of specimens of the positive control virus inoculated animals showed that about 
70% specimens showed grade one to two level effects which is also within the acceptable 
range for LOl/Mu90 strain as seen in other RNVT's (Tables 3.3 and 3.6).
In relation to other parameters discussed in section 3.1.1, the thickness of the cerebral cortex 
showed that one specimen (25%) had Grade One level effects (Appendix I). The negative 
control virus had one specimen, (12.5%) showing low-level effects, whereas the positive 
control virus had mainly Grade One level effects with a few being extended up to Grade Two.
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Table 3.6: Grading assessment of the Lateral Ventricle size of animals inoculated with mumps 
specific clinical sample and associated isolate.
Grading Clinical
Material
Sample
99-0333
Clinical
Material
Sample
99-0333V
Percentage 
of Controls 
for RNVT B
+
- 25 0 0 50
-/+ 0 0 10 37.5
+ 50 75 30 12.5
+ /+ + 25 25 20 0
++ 0 0 20 0
+ + /+ + + 0 0 10 0
+++ 0 0 10 0
Total 100 100 100 100
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Figure 3.15 : Grading assessment of the nine additional parameters of animals inoculated with
Clinical Material 99-0333
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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The 99-0333 clinical material and positive and negative control viruses had no detectable 
effects on any other parameters of the third ventricle (Appendix I). The 99-0333 material had 
more pronounced effects on the parameters of the lateral ventricle than the corresponding 
negative control virus. Two animals (50%) inoculated with 99-0333 material displayed Grade 
One level effects and one animal (25%) had Grade One/Two level effects. The positive control 
virus showed Grade One level effects on the epithelial layer (Appendix I). The sub-epithelial 
layer of the lateral ventricle in two specimens (50%) was effected by a Grade One and in one 
specimen (25%) by a Grade Two.
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Figure 3.16 : Grading assessment of the nine additional parameters of animals inoculated with
Clinical Material 99-0333V
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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The animals receiving negative control virus had low-level effects on the sub-epithelial layer 
whilst those receiving the positive control had Grade One and Grade Two level effects 
(Appendix I). The 99-0333 virus showed to be negative with a degree of low-level effect on the 
molecular layer of the cerebellum as did the negative control virus group. The positive control 
group mostly had Grade One level effects on the molecular layer and Purkinje Cell layer whilst 
one specimen had Grade Two level effects on the Granular Layer (Appendix I).
Both 99-0333 material and negative control virus showed no effects on the Granular Layer. The 
thickness of the cerebral cortex of animals inoculated with 99-0333V and negative control virus 
was not effected at all. Unlike the negative and positive control viruses, 99-0333V isolate had 
an effect on the third ventricle (Appendix I). One specimen (25%) had a Grade One level 
effects on the epithelial layer. One sample (25%) had low-level effects on the sub-epithelial 
layer and had no effects on the size of the third ventricle. The 99-0333V inoculated animals had 
3 specimens (75%) which showed Grade One level effects on the size of the lateral ventricle 
(Appendix I). One specimen (25%) had Grade One/Two level effects on the epithelial layer. 
Three specimens (75%) had Grade One level effects and one specimen (25%) had Grade Two 
level effects on the sub-epithelial layer. The negative control group had one specimen (25%) 
having Grade One level effects on the sub-epithelial layer. The 99-0333V isolate had one 
specimen (25%) showing Grade One level effects on the molecular layer (Appendix I). The 
other two parameters of the cerebellum region of the animals inoculated with 99-0333V isolate 
did not show any variations.
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3.3.5 Observations of Diluent Sample Inoculated Animals.
The animals discussed in this section were inoculated with the medium used to dilute the virus 
stock samples. Technically this is another version of the negative control material but for ethical 
reasons was not chosen for that purpose in this study. For the composition of the diluent 
sample see Section 2.1
Animals inoculated with the diluent material did not show many changes in the ventricle region 
of the brain (Table 3.7). About the same number of animals also did not show any changes in 
the negative control group. Flowever, in the diluent group one animal (5.3%) showed changes 
that is classified as Grade One (Figure 3.17). This could be due to an error in the slide reading 
or of the tissue processing procedure that may have caused tissue damage.
All of the additional parameters assessed were negative with the exception of the sub-epithelial 
layer of the lateral ventricle, that showed one specimen having low-level effects (Appendix I). 
The negative control virus group was also negative for all additional parameters except for the 
epithelial layer, sub-epithelial layer and size of the lateral ventricle (Appendix I). The positive 
control virus group displayed a mixture of negative, low-levels to positively detectable effects 
on all additional parameters as seen with the inoculated animals in other RNVTs in this study.
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Table 3.7: Grading Assessment of the Lateral Ventricle size of animals inoculated with the 
diluent sample.
Grading Diluent
Samples
Percentage of 
Controls for 
RNVT]
+
- 89.5 0 88.9
-/+ 5.3 12.5 11.1
+ 5.3 25 0
+ /+ + 0 0 0
++ 0 37.5 0
+ + /+ + + 0 0 0
H—1—h 0 25 0
Total 100 100 100
110
Figure 3.17: The Diluent Sample showing a Grade One effect
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Figure 3.18 ; Grading assessment of the nine additional parameters of animals inoculated with 
the Diluent
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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3.4 Histopathological data of samples obtained from FDA.
The table below shows a summary of data generated for the lateral ventricle size of brain 
samples of animals inoculated with five different samples received from FDA, USA. All samples 
were supplied and tested coded. The data presented in this section, therefore, could not be 
attributed to any particular strain of virus, mumps or otherwise, until the decoding is 
performed by FDA.
In this part, histopathological data of five different strains of mumps viruses, evaluated in 
five different tests are presented. The tests were conducted in the following formats:
RNVT F - FDA sample A 
RNVT I - FDA sample B 
RNVT D - FDA sample C 
RNVT E - FDA sample D 
RNVT H - FDA sample E 
Each RNVT had an appropriate positive control virus and a negative control virus, identical to 
the assay format applied for NIBSC mumps virus strains testing. The data shown in Table 3.8 
indicated that 31.6% animals inoculated with sample A did not present many effects on the 
lateral ventricle size. Sixty-three percent of animals showed low-level effects on the lateral 
ventricle size, whilst one animal (5.3%) had effects of the grade level One/Two (Table 3.8). In 
contrast, the animals Inoculated with sample B had more pronounced effects on the lateral 
ventricle sizes as all of the animals showed measurable effects ranging from Grade One to 
Grade Four.
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Sixty seven percent animals inoculated with FDA sample C had effects on the lateral ventricle 
size ranging from Grade One to Grade Two (Table 3.8). Thirty three percent of specimens could 
not be conclusively assigned into the negative group and therefore were given -/+  scoring. 
Thirty five percent of animals inoculated with FDA sample D were completely negative for any 
changes in the size of lateral ventricle (Table 3.8). Fifteen percent of animals could not be 
scored definitively and therefore were placed in the -/+  group. The remaining 50% of animals 
had variations in the size of lateral ventricle that ranged from Grade One to Grade Two. Finally, 
the animals inoculated with the FDA sample E did not show any changes in lateral ventricle size 
(Table 3.8).
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Figure 3.19 : Grading assessment of the nine additional parameters of animals inoculated with 
the FDA A Strain
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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Figure 3.20 : Grading assessment of the nine additional parameters of animals inoculated with 
the FDA B Strain
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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It is noticeable from data shown in Table 3.8 that all animals inoculated with the negative 
control virus preparation either showed no effects or had some low level effects up to Grade 
One. However, this was not seen in the RNVT I, where the animals inoculated with the negative 
control virus preparation had 28% of specimens showing Grade One or higher effects. This may 
attribute to the higher neurovirulence profile of FDA sample B.
In relation to the other parameters examined in this study, it was observed that the FDA 
sample A had low level effects (-/+ ) on the epithelial and sub-epithelial layers of the third 
ventricle as well as on the molecular layer of the cerebellum (Appendix I). The FDA sample B 
also had some low-level effects on the thickness of the cerebral cortex, the epithelial layer of 
the third ventricle and on the sub-epithelial layer (Appendix I). Animals inoculated with this 
strain also showed effects ranging from Grade One to Two for the size of the third ventricle and 
on the epithelial and sub-epithelial layers of the lateral ventricle. The FDA sample C had some 
effects in a minority of inoculated animals in the regions of the cerebral cortex, molecular layer 
of the cerebellum and the epithelial layer of lateral ventricle. One specimen which displayed a 
low-level effect in the molecular layer of cerebellum also had a very low level effect on the 
Purkinjie cell layer but no effect on the Granular layer (Appendix I)
The FDA sample D did not show any effects in the inoculated animals on the size of the third 
ventricle but displayed low-level effects on the epithelial and sub-epithelial layers (Appendix I). 
One specimen had a Grade One level effect on the size of third ventricle but this was not 
remarkable, as all other animals of this group did not show any effects on the third ventricle. 
Thirty eight percent of animals Inoculated with FDA sample D also had a Grade One level effect 
on the molecular layer, 5% on the Purkinjie cell layer and another 5% on the Granular layer 
(Appendix I).
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Figure 3.21 : Grading assessment of the nine additional parameters of animals inoculated with 
the FDA C Strain
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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Figure 3.22 : Grading assessment of the nine additional parameters of animals inoculated with 
the FDA D Strain
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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Figure 3.23 : Grading assessment of the nine additional parameters of animals inoculated with 
the FDA E Strain
Key: 1 Thickness of the Cerebral Cortex
2 Third Ventricle ; Epithelial changes
3 Third Ventricle ; Sub-epithelial changes
4 Third Ventricle ; Size
5 Lateral Ventricle ; Epithelial changes
6 Lateral Ventricle; Sub-epithelial changes
7 Cerebellum; Molecular layer
8 Cerebellum; Purkinje cell layer
9 Cerebellum Granular layer
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Interestingly, the FDA sample E did not show any recordable effects on the lateral ventricle size 
of the brains of inoculated animals, but did produce some effects. Grade One, in one animal on 
the thickness of cerebral cortex (Appendix I). The negative control virus inoculated animals also 
gave similar scorings. A few animals inoculated with FDA E sample also showed low-level 
changes in the epithelial layer of lateral ventricle and Purkinje cell layer.
3.5 FDA Scoring Procedure
The scoring of histopathological slides for lateral ventricle enlargement, carried out at FDA,
USA, was different to the method applied during this study. At NIBSC, the scoring was based 
on a visual observation, under microscope, where any enlargement in the size of the lateral 
ventricle region was assigned from being completely negative (-) to Grade Four (+ + + + ), in line 
with the scoring procedure developed for the monkey model (Afzal et al 1999a).
In contrast, the FDA procedure was based on recording a numerical value for the lateral 
ventricle region. The numerical value was the percentage area of the total brain that the lateral 
ventricle occupied, excluding the brain stem. This method gave an estimation of the degree of 
hydrocephalus caused in the brain.
Both the FDA and NIBSC samples were read using the in-house method as well as the method 
developed by FDA. Both sets of data are reported in Appendices I and III.
3.5.1 Calculation of mean values and their interpretation
In order to calculate the mean values of lateral ventricle areas, percentage figures obtained 
after each numerical recording were added together and then divided by the total number of 
samples examined in that group.
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Table 3.9: The lateral ventricle mean value using the FDA Scoring method.
Virus Group Group Mean Percentage of Lateral 
Ventricle Enlargement.
FDA B Sample 24.04%
Lol/Mu90 12.04%
FDA C Sample 5.71%
FDA D Sample 5.2%
JL5/4 4.8%
Nt5 Urabe Sample 4.4%
Clinical Material 99=0333/lV 3.5%
Clinical Material 99-0333 2.8%
Urabe Vaccine Bulk (SKB) 2.7%
FDA E Sample 2.58%
Lo4/2 Urabe Sample 2.0%
FDA A Sample 1.3%
JL2/4 1.0%
JL Vaccine Bulk (SKB) 0.42%
Diluent Only 0.28%
JL Vaccine Bulk (MSD) 0.14%
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The percentage mean values of the lateral ventricle area of the brain in each group of 
inoculated animals may be useful in predicting levels of neurovirulence of each mumps virus 
strain in neonatal rats.
The FDA B sample gave the highest mean percentage of all the samples tested, it showed to be 
twice as neurovirulent than the positive control Lol/Mu90 (Table 3.9). The JL MSD vaccine bulk 
had a mean percentage value of 0.14%, which was the lowest mean scoring. Interestingly, the 
diluent sample showed a group mean value of 0.28%. Although this score is higher than JL 
MSD vaccine bulk it is due to an anomalous sample (Figure 3.9, Table 3.7). The JL SKB vaccine 
bulk preparation that was routinely used as an assay negative control in this study had a 
percentage mean value of 0.42% (Table 3.9). As seen with the monkey neurovirulence studies, 
the JL vaccine based samples had less severe effects on the size of lateral ventricle in rats than 
the Urabe vaccine related samples.
The percentage mean values reported in Table 3.9 could be useful markers in establishing a 
correlation between various strains and their associated neurovirulent potential in neonatal rats. 
However, as seen with the data of the diluent Inoculated group, false results could easily 
contribute to the group average that may not necessarily be correct.
3.5.2 Unpaired Students T-test
The unpaired students T-test was applied to observe statistical significance between data sets 
in terms of the probability (P) value. The further away the P value is from 1.0, the less 
probability there is to suggest a statistical relationship between the two data sets. A 
relationship is considered to be relevant if the P value is above 0.01, the value represents a 
universal cut-off point. Conversly, two data sets are considered to be significantly different if 
the P value is less than 0.01 with increasing significance being attached to the difference with 
decreasing P values, below 0.01.
Using this test, it was possible to distinguish between wild-type and vaccine strains of mumps 
in terms of their neuropathological performances in the neo-natal rat model.
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Animals inoculated with Lol/Mu90 did not show any relationship, in terms of P values, with any 
other strain tested. In this analysis, the Loi strain closely resembled the clinical material 99- 
0333 (P 0.023) and its cell culture harvest 99-0333/lV (P 0.035). But the significance of this 
relationship can not be conclusively predicated as the dose of the clinical material and its cell 
culture harvest was not critically defined. The positive control virus, Lol.Mu90, was also 
statistically different than the negative control (P 7.9x10'^).
In terms of neuropathological effects the negative control virus, SKB JL vaccine bulk, showed 
relationships with unpassagaed clinical material sample 99-0333 (P 0.748) and the culture 
harvest of the clinical material 99-0333/lV (P 0.984), JL5/4 (P 0.122), JL2/4 (P 0.063) than the 
other strains.
In terms of the P value, a stronger relationship was observed between the diluent sample and 
MSD JL vaccine bulk preparation (P 0.499), both of which showed very little, or no, effects on 
the lateral ventricle size enlargement in the inoculated rats.
Interestingly, the MSD JL vaccine bulk did ot show any neuropathological resemblance with its 
two sub-component viruses, JL5/4 (P 6.799x10'^) and JL2/4 (P 6.72x10'^); and was statistically 
different from them. The sub-components were given four passages in Vero cells.
The SKB Lira be vaccine bulk show significant neuropathological resemblance with the clinical 
material 99-0333 (P 0.908) and its cell culture harvest 99-0333/lV (P 0.838), SKB JL vaccine 
bulk (P 0/935), Nt5 (P 0.149) and Lo4 (P 0.258) isolates. This indicates that strains with minor 
differences in their neurovirulent properties would be difficult to distinguish with this test.
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Table 3.11: The P values of viruses obtained from the FDA.
FDA A FDAB FDAC FDAD FDAE
FDA A - 7.107X10-^2 6.9X10'® 0.004 0.242
FDAB 7.107X10^2 - 1.26X10® 1.08X10-3 3.44X10-"
FDAC 6.9X10-S 1.26X10'^ - 0.972 0.0791
FDAD 0.004 1.08X10® 0.972 - 0.058
FDAE 0.242 3.44X10'” 0.0791 0.0791 -
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Given the fact that the identity of the FDA samples are not in at this time it is diffcult to surmise 
if the differences seen in the p values in Table 3.11 would bear any descriptive values.
However, the data presented above indicates that the FDA A sample is significantly more 
related to samples D and E than samples B and C. Hpwever, FDA B sample is unique in its 
neuropathological characteristic, similar to the NIBSC Lol/Mu90 strain, and does not resemble 
any other strains tested in the panel. In terms of p values the sample C is more closer to 
samples D and E than samples A and B. It remains to be seen whether the clinical and isolation 
details of these strains also support the association established on the neuropathological profile 
observed in this study.
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4 Discussion
Mumps is a common childhood illness which is characterised by swelling of the parotid glands. 
Its viral aetiological agent was originally identified by Johnson and Goodpasture in 1935.
Mumps virus is transmitted by droplet spread and infects the nasal and upper respiratory 
mucosal epithelium. Dissemination of the virus leads to infection of the visceral organs and the 
central nervous system. This can cause a variety of mumps-associated complications including: 
epididymo-orchitis, pancreatitis, meningo-encephalitis and spontaneous abortion (see Section 
1.1). Prophylactic vaccines have led to a reduction in the number of cases of mumps illness and 
its associated clinical complications.
It has been observed that some brands of vaccines, notably those containing the Lira be, L-3 
and LZ strains, are associated with significant adverse effects in vaccine recipients. The 
complications range from minor allergic reactions to meningitis and encephalitis. These vaccines 
were tested by the manufacturers using the monkey neurovirulence test during the stages of 
vaccine development and evaluation. However, it is understood the test had failed to detect, or 
predict the lack of, virulence that may be associated with these vaccines for human recipients 
(Buynak and Hilleman, 1966). Therefore, it is vital that alternative animal models, in addition to 
the monkey model, should be explored on the assumption that one may prove to be a better 
substrate for the prediction of vaccine associated neurovirulence.
The European Pharmacopoeia stipulates that all live viral vaccines are to be tested in monkeys 
for side-effects, including neurovirulent activity, before being licensed for public use. While the 
monkey model works satisfactorily to test polio and yellow fever vaccines it has not been a very 
accurate predictor of the neurovirulent potential of mumps vaccines. The current monkey model 
requires the inoculation of mumps vaccine preparation directly into the brain of ten animals 
which, after an incubation period of three to four weeks, are examined histopathologically for 
any signs of virus specific lesions in the brain.
A Japanese group has recently investigated the marmoset model for mumps neurovirulence
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testing and preliminary results are appealing (Saika et al 2002). However, a model based on 
small laboratory animals for mumps vaccine neurovirulence testing is highly desirable for 
several reasons including the ethics, cost, ease of maintaining and handling animals and other 
technical grounds under which large number of animals could be used to generate statistically 
meaningful data.
In the current study, Lewis rats were inoculated with mumps virus vaccines, vaccine associated 
isolates and wild type virus some of which had been tested in the monkey model previously at 
NIBSC or elsewhere (Rubin et al 1998a, 1998b, 2000). The key objective of this study was to 
evaluate the rat model for its susceptibility to various mumps virus vaccine strains and to 
identify whether the test could discriminate between closely related vaccine preparations which 
may or may not be suitable for immunisation.
4.1 Lateral ventricle size variation - a kev parameter
It has been shown by Rubin et al (1998a, 1998b; 2000) that the lateral ventricle of the neonatal 
rat brain is the most susceptible area showing histopathological alterations following I.C. 
inoculation of mumps virus strains. It is suggested that the change in the size of the lateral 
ventricle is induced by an alteration in the equilibrium flow of the cerebrospinal fluid. The virus 
is thought to infect the cells surrounding the ventricle which control this process, resulting in an 
increase in the flow of CSF into the ventricular space and distending the lateral ventricle. This 
causes a pathological condition known as hydrocephalus. This project is aimed to examine the 
degree to which a particular mumps virus strain distends the lateral ventricle over a given study 
period, which is speculated to be linked to the neuroinvasive properties of the strain in 
developing rat brains.
4.2 The Jeryl Lynn vaccine group.
The JL vaccine strain specific materials used in this study were derived from the following 
different sources:
JL-MSD vaccine bulk
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JL-SKB vaccine bulk 
JL2/4 isolate from JL-MSD vaccine bulk 
JL5/4 isolate from JL-MSD vaccine bulk 
The difference between the two vaccine bulks is based on the residual virus components, which 
in the case of JL-MSD has both the JL-2 and JL-5 sub-variants. In contrast, JL-SKB vaccine is 
derived from the JL-5 sub-variant. Both vaccines have been licensed in the UK and several other 
countries. None of the JL based vaccines has been associated with the induction of any serious 
adverse effects in vaccinated children. Based on the proven clinical safety of these vaccines, 
and considering the residual component purity of the vaccine(s), it was considered that JL SKB 
vaccine bulk preparation would be suitable to be used as a negative control material in this 
study. Histopathological data of the lateral ventricle of brains of animals inoculated with various 
versions of the JL strain revealed that between the two commercial vaccines, the JL SKB 
material was slightly more reactive than JL MSD vaccine bulk. While the JL MSD vaccine 
preparation did not produce any effects in any inoculated animals, the JL SKB vaccine 
preparation had Grade One level effects in 3.4% of animals and very low levels effects on 
another 40% of inoculated animals (Table 3.3). These findings are further supported by data 
presented in Table 3.10 which indicate that the mean group percentage for the lateral ventricle 
size was 0.14% for JL MSD vaccine and 0.42% for JL SKB vaccine. This may be wholly 
attributed to the component variability of the two vaccines or the JL5 component of the JL SKB 
vaccine bulk may have gained increased neurovirulence during its passaging in cell culture after 
isolation from MSD vaccine.
Human recipients of the JL SKB vaccine show no significant adverse events and so the low level
of neurovirulence associated with it in this study may not have any cause for concern.
Additionally, between the two component viruses of JL vaccine, JL2/4 and JL5/4, that were
passaged 4 times in Vero cells, the JL-5/4 was shown to be more neurovirulent than JL2/4
(Tables 3.4 and 3.9). This adds to the earlier speculation made above that the JL5 sub-variant
may gain some virulence during cell culture passaging. It is also noteworthy that JL5/4 was
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passaged in Vero cells while the JL5 clone originally used by SKB to generate the vaccine seed 
was isolated and passaged in CEF cells.
All JL strain associated viruses were examined in two tests, RNVT E and RNVT G, which showed 
a slight discrepancy between them in terms of the overall performance of positive control virus 
samples. While in RNVT E the positive control sample produced more than Grade One level 
effects in nearly 100% of animals this was not seen in RNVT G where similar effects were 
observed in only 60% of animals. This could be due to an experiment to experiment variation, 
though overall in this study the experimental consistency was reproducible (see Table 3.3). It 
was thought that further passages of vaccine strains in vitro would lead towards further 
attenuation of the virus; however, data presented in this study does not support this notion. It 
is possible that the vaccine virus may generate a progeny of sub-variants during in vitro 
culturing that contribute to the enhancement of neurovirulence in comparison to the original 
vaccine bulk. It would be interesting to characterise the cell culture harvests of JL2/4 and JL5/4 
to identify the existence of the quasi-species present.
The results of neurovirulence testing of JL based vaccines could be compared to their 
characteristics in the field. In the RNVT's, JL vaccine inoculated animals showed little or no 
neurological effects which confirms the clinical safety of these vaccines. The rat model has also 
shown the possibility that further passaging of JL viruses in Vero cells increases the 
neurovirulent potential of the virus.
The data presented conclude that the neo-natal rat model is able to distinguish between the 
vaccine strain and some of its derivatives.
4.3 The Urabe vaccine group.
There were three different preparations related to Urabe vaccine virus which were evaluated 
in this study. They are described below and in Chapter 2.
SKB -Urabe vaccine bulk
Lo4/2, a post-vaccine isolate from an asymptomatic individual, grown in Vero cells
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Nt5, a post-vaccine isolate from a symptomatic individual grown in Vero cells.
Urabe mumps vaccine has been implicated in the development of aseptic meningitis and other 
complications in vaccine recipients. Due to these reasons the vaccine was withdrawn from the 
immunisation schedule in the UK in 1992.
The Urabe vaccine was produced from a plaque picked clone and therefore it was thought that 
the finished vaccine preparation would contain no residual component viruses. However, 
nucleotide sequence analyses of the Urabe vaccine strain and of isolates derived from healthy 
or diseased individuals following vaccination with Urabe revealed the existence of an additional 
population of virus' in the vaccine, which had accumulated point mutations in various regions of 
the genome (Afzal et al 1994, Yates et al 1996, Brown et al 1996). Examination of the HN 
region of the additional viruses has identified a mutation at amino acid 335 which may play a 
role in both defining the antigenicity of the virus as well as in inducing a neutralising antibody 
response in vaccine recipients. It has been suggested that amino acid 335 of the HN protein 
maybe associated with the virulence and attenuation of Urabe mumps vaccine strain (Brown et 
al 1996, Afzal et al 1998). All Urabe vaccine associated isolates that were originally derived from 
vaccinees with a range of post-vaccination adverse effects, ranging from swollen glands to 
meningitis, have had a lysine amino acid residue at position 335 of the HN protein gene 
sequence, while isolates derived from healthy individuals, who did not show any symptoms 
following Urabe mumps vaccination had a glutamic amino acid residue at this position. It is 
notable that the Lo-4 isolate had a glutamic acid residue, and Nt5 had a lysine residue at 
position 335 of the HN protein (Afzal et al 1998).
The data regarding the lateral ventricle size of the Urabe group presented in Tables 3.5 and 3.9
show that amongst the viruses tested, the animals inoculated with SKB-Urabe vaccine bulk
(2.7%) and Nt5 (4.4%) were more severely affected than the animals inoculated with Lo4
(2%). In the Lo4 group, only 10% of animals showed effects that could be graded to level one,
while both in SKB-Urabe vaccine bulk and Nt5 inoculated animals nearly 40% of animals
showed effects that were graded from levels One to Two. It is notable that the negative control
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virus in RNVTs B and D, in which SKB-Urabe vaccine bulk and Nt5 preparations were examined 
respectively, showed a slightly higher background scoring than seen in RNVT F, where the Lo4 
was tested. This discrepancy, if taken into account, could only lead to a reduction of 10% of 
animals currently classified in higher groups of SKB-Urabe vaccine bulk and Nt5 inoculated 
animals. The fact that both SKB-Urabe vaccine bulk and Lo4 presented almost the same degree 
of neurovirulence scoring pattern in neonatal rats is interesting and could lead one to speculate 
that the SKB-Urabe vaccine bulk may be mostly composed of the Lo4 type sub-component. 
Alternatively, it is also possible to suggest that the Nt5 type component present in the Urabe 
vaccine bulk is slower to replicate in rat brains than the Nt5 type component grown in tissue 
culture. The composition, in terms of residual sub-variant in SKB-Urabe vaccine bulk used 
should be determined in future investigations.
Further analysis of Table 3.9 shows that the degree of enlargement of the lateral ventricle size 
was much more severe in animals inoculated with Nt5 than animals inoculated with unpassaged 
vaccine bulk. This confirms the notion that passages of mumps virus in Vero cells may 
contribute towards the enhancement of neurovirulence for the rat brain.
4.4 The Clinical Material Group
All previous studies related to the neurovirulence testing of mumps virus have been carried out 
with vaccine preparations or wild type strain preparations grown in cell culture. The assessment 
of unpassaged mumps specific clinical material for neurovirulence, in line with other culture 
isolates and vaccine preparations, has never been performed in any animal model. In this 
respect the current study is novel and unique. The clinical material designated, 99-0333, was 
originally derived in 1999 from a child with parotitis and was supplied to NIBSC by the Health 
Protection Agency, Colindale, London. This material was passaged once in Vero cells to produce 
the second generation material designated as 99-0333V. Neurovirulence data of lateral ventricle 
size enlargement reported in Table 3.6 showed that 75% of animals inoculated with 99-0333 
material had Grade One level or higher effects. This is in contrast to 99-0333V inoculated
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animals where 100% of animals showed Grade One or higher level effects leading to the 
suggestion that the cell culture harvest was possibly more virulent than the original clinical 
material. However it is important to report that the clinical sample, as well as its associated cell 
culture derived harvest, was inoculated into only four animals. Additionally, both preparations 
were not titrated to determine their virus titres; therefore, the two group of animals may have 
received unequal amounts of infectious virus and the observed discrepancies could be 
due to the dosage variability. A larger number of animals should be inoculated to obtain 
statistically meaningful results. Additionally, based on the scoring profile of the negative control 
virus inoculated animals in RNVT B, it is reasonable to suggest that some animals may have 
been artificially scored higher due to the overall higher test background readings.
4.5 The Diluent Group
The diluent comprised MEM that was used to dilute stock virus preparations prior to the 
inoculation of animals. Although MEM could have been used as the main negative control 
sample in the RNVTs conducted, the SKB JL vaccine bulk preparation was used as the principle 
negative control sample throughout this study. This was for historical reasons as the JL SKB 
based mumps vaccine has not been shown to be associated with any neurovirulence in vaccine 
recipients. The use of the diluent as a negative control sample in each assay could have been 
viewed as an unnecessary waste of animals.
It is interesting to observe that data shown in Table 3.7 reveal that nearly 90% of animals 
inoculated with the diluent sample as well as those with the negative control virus preparation 
show no evidence of mumps virus specific effects in the lateral ventricle regions. The remaining 
10% of animals of the negative control virus group had very low level effects. With respect to 
the remaining 10% of animals of the Diluent group, it was observed that one specimen (5%) 
had a Grade One level effect while the other specimen may or may not have had any effects in 
the lateral ventricle size. As the diluent sample was free of any viral residues it is understood 
that the one specimen which showed a Grade One level effect was an experimental artefact.
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This damage may have been caused by the needle track during I.C. inoculation or damage may 
have occurred to the tissue section during the experimental processing. It is also possible that 
the diluent medium itself might have been injected directly into the ventricular cavity causing an 
irreversible alteration in the size of the lateral ventricle. Many animal models note discrepancies 
of this nature including the macaque models of HIV. This also highlights the need for several 
animals to be studied in each experiment in order to minimise experimental anomalies.
4.6 Role of positive and negative control virus preparations in the assessment of RNVTs.
For logistical and technical reasons it was not possible to inoculate more than 60 animals per 
experiment in this study. One way to identify variations between individual RNVTs conducted at 
different time periods was to include some common samples in each test. For this reason, two 
preparations, one to be used as a positive control. Loi/ Mu90, and other to be used as a 
negative control, SKB-JL vaccine bulk, were evaluated in each test. The combined data of the 
lateral ventricle size alterations (Table 3.3; Table 3.8; Table 3.9) show that of all the viruses 
tested the Loi preparation was most neurovirulent. This confirms previous results of this 
preparation as assessed in the monkey model by Afzal et al (1999a).
However, test to test variations were observed with respect to the scale of the enlargement of 
the lateral ventricle size, although overall all animals presented with almost similar effects. The 
majority of the samples were in Grade One to Grade Two range, only 3 RNVT's demonstrated a 
Grade Three effect and 2 RNVT's a Grade Four effect. The virus preparation that was used as a 
negative control also produced consistent data, although RNTV B, RNTV D and RNVT I showed 
some higher background scorings but they were observed with one or two specimen(s) only.
In summary, the use of Loi and SKB JL vaccine bulk has proved to be a useful choice to 
assess the performance of any individual RNVT against the cumulative data of the study.
4.7 Additional Parameters
Based on previous results published by Rubin et al (1998b) it is understood that enlargement of
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the lateral ventricle following mumps virus I.C. inoculation would remain a key parameter to 
predict the levels of virulence that may be associated with any given strain of mumps virus. 
However, in this study nine other parameters were also examined with the objective that their 
histopathological observations may provide some further information that could be used for an 
accurate strain specific neurovirulence prediction in the neonatal rat model.
4.7.1 Thickness o f the Cerebrai Cortex.
The thickness of the cerebral cortex alters as a result of infection with MuV. During the course 
of this project, it was noted that this alteration seemed to be dependent on the enlargement of 
the lateral ventricle. It was noted that with all the viruses studied, including the positive and 
negative controls, as the size of the lateral ventricle increases, the size of the cerebral cortex 
decreases, showing an inverse relationship between the two parameters.
The viruses which showed no increase in the lateral ventricle size, such as JL MSD vaccine bulk, 
also failed to show any decrease in the thickness of the cerebral cortex. Viruses displaying an 
enlarging effect on the lateral ventricle; Lol/Mu90, SKB Urabe Bulk Vaccine, Nt5 Urabe strain, 
JL5/4 vaccine sub-component, and the clinical material 99-0333, also exhibit a decreasing effect 
on the thickness of the cerebral cortex.
Viruses displaying a slight enlarging effect on the lateral ventricle; JL2/4 vaccine sub-component 
and Lo4 do not show any variation in the cerebral cortex thickness. This could be due to the 
fact that the enlarging effect on the lateral ventricle region is very small and did not exert 
significant pressure on the cerebral cortex to produce a measurable effect. However the clinical 
isolate, 99-0333V, had Grade One and Two level effects in the lateral ventricle but no 
detectable effects on the thickness of the cerebral cortex leading to the suggestion that either 
the correlation between the two parameters is not accurate or an insufficient number of animals 
were studied in the clinical material sub groups to identify any cerebral cortex variability.
Further investigations are needed in this direction.
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4.7.2 The Ventricles.
Rubin et al (2000) noted that after MuV i.e. inoculation the third ventricle increases in size but 
the enlargement is small in comparison to the scale seen in the lateral ventricle region. The 
results of this study support their observations. It was noted during this study that of the 
viruses which had an effect on the third ventricle; SKB JL Vaccine Bulk and Lo4, the most visible 
effects were seen on the epithelial layer of the ventricle. This would be consistent with what is 
known of MuV infection; if MuV had an affect on the third ventricle, the cells surrounding the 
ventricle would be the first cells to show evidence of the infection. Once those cells had altered 
the equilibrium flow of the CSF into the ventricle, it would enlarge. As the incubation period of 
the virus in this study was only 30days, it is possible that the virus needs a longer period to 
reach to the cells surrounding the third ventricle. It would be useful in further studies to use 
immuno-histo staining methods to identify the localisation and distribution of the mumps virus 
within various regions of the inoculated brain.
The current results are inconclusive in predicting whether or not oedema occurs before or after
the ventricle starts to enlarge. It appears that in most cases; Lol/Mu90, JL2/4, JL5/4, Nt5, FDA
A, B and D strains, the oedma may have started to occur after the ventricle has begun to
enlarge, this is known by the degree to which each change has occurred. The SKB Urabe
Vaccine, 99-0333V and FDA A strain inoculated specimens suggest that oedma may have
occurred before the ventricle starts to enlarge. These results imply that after MuV has infected
the epithelial layer, the CSF accumulates in the surrounding tissue before invading the ventricle.
As infection seems to be established in the lateral ventricles of all neurovirulent viruses it is
difficult to determine the course of the infection. Once the epithelial layer shows signs of
infection it can be assumed that the course of infection has started, it is unclear if the grading
of the epithelial layer would increases over the prolonged incubation.
Taking only the size of the lateral ventricle and the surrounding oedma into consideration, the
results for the lateral ventricle suggest that the majority of viruses have the enlarging effect
before oedma occurs; JL5/4 and 99-0333 are the only viruses that suggest otherwise. This
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would be the more logical course of the infection.
4.7.3 Epithelial Layer
The ability of the epithelial layer to be regarded as an additional marker for mumps 
neurovirulence in the rat model could be considered after further investigations in which 
inoculated animals should be incubated for various time periods are performed. The observation 
of this parameter in conjunction with the observation of the enlargement of lateral ventricle size 
would be very useful for specimens that could not be scored unambiguously and therefore give 
anomalous results.
4.7.4 The Cerebellum
Viruses which showed a neurovirulent effect on the cerebellum probably display one of the two 
below mentioned courses of infection.
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Figure 4.1 : Saggital cross-section of a normal cerebellum of a neo-natal rat brain
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The first possibility is that the virus may enter the cerebellum from the adjacent cerebral cortex 
and infects the Molecular Layer (ML) causing cells of the ML to migrate and accumulate. The 
virus infection then moves to the Purkinje Cell Layer (PCL) where it causes accumulation of cells 
on the tips of the PCL folds in the Granular Layer (GL). If the virus is extremely neurovirulent, 
the cell accumulations can bud off into the GL. The GL was rarely seen to be infected in this 
study, but when it showed any sign of infection, it was mild.
According to the second theory the virus affects all three layers simultaneously but infection 
takes longer to establish in the granular matter and PCL than the molecular layer.
The former theory is more convincing as the virus likely spreads from cell to cell in the cerebral 
cortex, after which the virus would penetrate the ML of the cerebellum.
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Figure 4.2 : Saggital cross section of the cerebellum of a neo-natal rat brain showing MuV 
infection.
Showing an infected cerebellum, indicating the extent that the cells in the ML migrate and 
aggregate, as well as the accumulation of the PCL cells. This differs from the normal
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cerebellum, Figure 4.1.
The cerebellum region could also be a good area to assess the damage caused by the virus 
following I.C. inoculation. Throughout this study a change in any of the layers of the cerebellum 
was always accompanied by a change in the size of the lateral ventricle. However, it is not 
speculated that cerebellum changes are a direct result of the enlargement of the lateral 
ventricle size, as both areas could be independently sensitive to mumps virus infection.
4.8 FDA Scoring of Samples
4.8.1 NIBSC Samples
Both scoring methods, in house as well as the one developed at FDA, produced data sets that 
were comparable with each other. For instance, the data produced by assigning plus/minus 
scores in relation to the enlargement of the size of the lateral ventricle region demonstrated 
that the Loi preparation was the most neurovirulent amongst all strains tested. This could also 
be concluded from the data obtained following the numerical scoring procedure. A similar 
correlation can be observed with the JL SKB vaccine bulk preparation that was used as a 
negative control throughout this study. It has been observed in this study that the JL SKB 
vaccine preparation is significantly more virulent than the JL MSD vaccine preparation, 
confirming a previous study that also observed this pattern (Afzal et al 1999b). This raises a 
question mark on the suitability of the JL SKB vaccine to be used as a genuine negative control. 
The JL SKB vaccine was selected as the negative control in this study for several reasons: A) It  
has not been associated with the development of meningitis in vaccine recipients, though 
similar could be argued for the JL MSD vaccine, B) unlike the JL MSD vaccine which is 
composed of two sub-variant virus populations the JL SKB vaccine is pure in its composition as 
it is derived from a single plaque picked virus stock. As one of the objectives of this study was 
to evaluate whether the neurovirulence test could be conducted in a reproducible fashion, it 
was vital to include a control preparation whose viral composition was relatively pure. The SKB 
JL vaccine bulk lot fulfilled that criterion.
152
Broadly, both scoring methods gave a similar conclusion; however, raw data obtained following 
the FDA scoring approach were user friendly for statistical analyses. It is vital that in each group 
a large number of animals should be inoculated to yield statistically meaningful results. The 
data reported in Tables 3.4, 3.7 and 3.9 indicate that the virus free diluent sample appears 
more virulent than the MSD JL vaccine bulk preparation which contained both JL2 and JL5 sub­
variants. The higher virulence of the diluent sample is based on the observations of a total of 19 
specimens, one of which had low level (+ /-) effects and one had grade one level effects on the 
size of lateral ventricle. The remaining 17 animals did not show any histopathological 
abnormalities. The higher group mean percentage of lateral ventricle size shown in Table 3.9 is 
principally based on the reading of one sample that showed very high lateral ventricle 
enlargement, which was not seen with any other animals in this group. Therefore, this reading 
must be considered as an experimental anomaly in this study.
Overall, the consistency between various RNVTs conducted in this study was good and 
reproducible, both negative and positive control virus preparations played a key role in 
demonstrating this. The results of clinical specimen, 99-0333, and its associated tissue culture 
grown material, must be read with great care. This is due to the fact that only four animals 
were inoculated with each sample and, therefore, any experimental anomaly, as seen with the 
diluent inoculated group, would have had a large effect on the group average score. Further 
studies, using more animals, are vital to draw any final conclusion about the performance of the 
clinical, and low passage level, samples in the rat model in relation to other vaccine and wild 
type strains.
It is interesting to observe that the JL MSD vaccine bulk lot, which contained both JL2 and JL5
residues scored 0.14% on the group mean index (Table 3.9) where its plaque purified, Vero cell
grown, components scored 1.0% and 4.8% respectively. This indicates that a combined version
of JL2 and JL5 is less virulent than the culture grown viruses. It is widely believed that the
passaging of viruses in culture induces attenuation and, therefore, should lead to a reduction in
the virulence of the virus. However, this was not observed with the JL vaccine strain viruses. It
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would be of further interest to note if the SKB JL vaccine which is exclusively made of the JL5 
component, could also gain virulence following in i//Ï7ï> passages in Vero cells.
The Urabe vaccine, which has been definitively associated with post-vaccine aseptic meningitis 
in children, scored 2.7% on the group mean index (Table 3.9) which is higher than the Lo4 
index (2.2%) but lower than the NTS index (4.4%). Both Lo4 and Nt5 viruses have been serially 
passaged in Vero cells. The Lo4 was originally isolated from a healthy child, and Nt5 from a sick 
child, both of whom were given SKB MMR vaccine that contained the Urabe mumps virus. The 
effect of in vitro passage of the Urabe related viruses is different from that of the JL related 
viruses. Compared to the vaccine virus, the Lo4 virus lost virulence while the Nt5 virus gained 
virulence, with both viruses having been passaged in Vero cells after isolation. This leads to the 
speculation that the neurovirulent potential of mumps vaccines is probably substrate dependent 
and passaging in Vero cells may enhance neurovirulence.
It is also interesting to note that the JL5 component of MSD JL vaccine, passaged in Vero cells, 
has a lateral ventricle size index almost similar to the index of the Nt5 isolate. More 
interestingly, the JL5 based vaccine, SKB JL, is also 4 to 5 passages away from the MSD JL5 
vaccine version, but proven to be clinically safe and has a lateral ventricle index of 0.42%. The 
difference between the JL5/4 and JL5 in SKB JL vaccine lies in terms of the cell substrates used 
for propagation. The JL5/4 was propagated in Vero while the JL5 in SKB JL vaccine was 
propagated in CEF cells. It is reasonable to suggest that CEF's have more attenuating effect 
while the primate cell line, Vero, has the opposite effect on the neurovirulence of mumps 
viruses in the rat model.
Based on the statistical data reported in Table 3.10 it is possible to suggest that the test could 
differentiate the wild type strain. Loi, from the other strains examined in this study. The test 
could also distinguish the Urabe vaccine lot from the JL based vaccine lots.
4.8.2 Classification o f FDA samples
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Although the identity of viruses obtained from FDA, USA, is not known at this time, it is possible 
to assign them a putative designation based on their neurovirulence profiles observed in the rat
model experiments at NIBSC.
As the FDA A sample displays many histopathological features that are common with the strain 
used as a negative control in this study it is possible to suggest that this sample may be related 
to or of a similar strain to the SKB JL vaccine bulk lot.
FDA B sample is more neurovirulent than the Lol/Mu90 strain, concluding that it is either a wild 
type strain or a neuro-adapted strain of virus.
FDA C sample a level of neurovirulence greater than any NIBSC sample except the positive 
control Lol/Mu90.
FDA D sample shows similar neurovirulence to the FDA C sample. This too may be a vaccine 
virus.
FDA E strain characteristics closely resemble to the negative control samples, therefore it may 
be a virus with no neurovirulent activity or no virus.
However, it is essential to emphasise that the above mentioned classification of FDA strains is 
purely a prediction, based on histopathological data of lateral ventricle size enlargement 
collected at NIBSC, it may differ when the actual sample codes are revealed after full data 
analyses by NIBSC and the FDA.
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5. Conclusions
The key objective of this study was to evaluate the neonatal rat model for its ability to 
distinguish between various preparations of mumps viruses belonging to vaccines or wild type 
phenotypes. In addition, the model was also tested for its reproducibility, consistency and 
accuracy by using blinded samples that were exchanged between the two laboratories, NIBSC, 
UK, and FDA, USA. Assays were conducted in both laboratories independently using identical 
scoring methods. The key conclusion of this study is that all strains that were distinguishable 
from each other in the monkey were also distinguishable from each other in the neonatal rat 
model. This alone is sufficient to suggest that the future mumps neurovirulence studies could 
be conducted on rats rather on monkeys. However, further work is needed to refine the 
methodology, in terms of the inoculation dose, study period, histopathological processing of 
tissues and slide readings, and in the selection of negative and positive control samples. In the 
current format the neonatal rat model could clearly distinguish between:
- Wild type strain and vaccine strains.
- Mumps vaccines of different strains, e.g. JL derived vs Urabe derived.
- Mixed or pure vaccine preparations of JL strain, e.g. SKB JL vs MSD JL
- The two residual components of MSD JL vaccine propagated in Vero cells from its 
progenitor vaccine lots.
Although several parameters of the brain were investigated in this study, no parameter other 
than the lateral ventricle size enlargement was considered to be a suitable predictor of mumps 
neurovirulence. Histopathological examination of the cerebellum region could complement the 
results of lateral ventricle size enlargement region and this correlation could be used to confirm 
ambiguous results.
Undoubtedly, the neo-natal rat model is a more convenient animal system than the macaque 
model for its inherent advantages related to ease, cost, management and utility of large
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number of animals per experiment and, therefore, would produce statistically meaningful data. 
More thoughts are needed to be given to decide about the preparation intended to be used as a 
negative control in future investigations. The MSD JL vaccine bulk lot was least neurovirulent in 
this study but it lacks residual component purity. The SKB JL vaccine bulk lot is pure in its 
composition but it was shown to have a measure of neurovirulent effect on the lateral ventricle 
size of the neo-natal rat brain.
The samples used in this project are listed in the table below according to their 
neurovirulent activity.
Table 5.1: Summary of the neurovirulence of the specimen used in this project, in 
descending neurovirulent activity.
Virus Comments Percentage Mean Scoring
FDA B sample Unknown sample 24.04
Lol/Mu90 wild-type virus Isolate from parotitis case, 
neurovirulent in monkeys.
12
FDA C sample Unknown sample 5.71
FDA D sample Unknown sample 5.2
JL5 (x4 vero passages) Component of MSD JL 
vaccine bulk
4.8
Nt5 Isolate from symptomatic 
vaccinee
4.4
Clinical Material 99-0333V Isolated from parotitis case 3.5
Clinical Material 99-0333 As above with x l vero 
passage
2.8
Urabe SKB vaccine bulk Vaccine implicated in 
adverse events
2.7
FDA E sample Unknown sample 2.58
Lo4 (x2 vero passages) Isolate from asymptomatic 
vaccinee
2.0
FDA A sample Unknown sample 1.3
JL2 (x4 vero passages) Component of MSD JL 
vaccine bulk
1.0
SKB JL vaccine bulk Vaccine with no known 
adverse events
0.42
Diluent Non-neurovirulent 0.28
MSD JL vaccine bulk Current vaccine not known 
to cause adverse events.
0.14
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&, Future Studies
In future projects, it would be useful to study the effect of passaging vaccine sub-populations 
and other non-neurovirulent mumps viruses in Vero and CEF cell substrates to detect any 
evident change in the virulence of the virus. It would also be interesting to note if the degree 
and nature of any change is dependent upon in which cell substrate the virus has been 
propagated.
This study shows that the neo-natal rat model could not distinguish between a neurovirulent 
and non-neurovirulent (good and bad) vaccine preparations. It also suggests that analysing 
events in the cerebellum may confirm or disprove ambiguous data. Immuno-histochemical 
staining could be used to determine the presence and localisation of the mumps virus within the 
brain. Molecular detection using RT-PCR approaches could also be performed for a more 
definitive method of virus detection.
This study also proves the need for a clearly defined positive and negative control for the neo­
natal rat model before it is suggested to replace the current macaque model.
The animals used in this study were incubated for thirty days post inoculation. Using a specified 
time period coupled with immuno-histochemical staining, RT-PCR, or in-situ hybridisation, it 
may be possible to determine not only the presence of mumps virus in the neo-natal rat brain 
but the course of the infection it pursues.
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7. Evaluation of Coded FDA Samples
The coded viral samples received from the FDA were uncovered at the viva voce. 
Table 7.1: Summary of the uncovered virus samples received from the FDA.
FDA Code FDA Descriotion
A Jeryl Lynn unpassaged monovalent mumps 
vaccine. By Merck and Co
B 88-1961. Wild-type strain isolated from saliva 
of patient with parotitis and symptoms of CNS 
infection. Passaged twice on vero cells
C Pariorix, unpassaged mumps monovalent 
vaccine consisting of attenuated Urabe-AM9 
strain. By GlaxoSmithKline.
D 87-1004. Pariorix post-vaccine derived isolate, 
obtained from CSF of patient with vaccine- 
associated meningitis. Passaged twice on Vero 
cells
E JL P3. Merck and Co's vaccine passaged three 
time on vero cells
Table 5.1 shows the results of this study in descending neurovirulent activity. With the FDA 
samples showing the order B, Q D, E and A. Once this information is applied to Table 7.1, it 
can be seen that the FDA blind study lends weight to the rat model being used as a tool for 
detecting neurovirulent activity of mumps.
Table 5.1 shows that FDA B sample is the most neurovirulent of all samples, with a 24.04% 
scoring of the lateral ventricle size. This sample is isolated from a patient displaying symptoms 
of CNS infection concurrent with the studys findings. The NIBSC lateral ventricle data also 
shows that this sample, showed no negative samples and went as high as a + + + +  grading for 
lateral ventricle size, the highest of all the gradings.
The FDA C sample has a mean scoring of 5.71% for lateral ventricle size, showing a degree of 
neurovirulent activity. It also showed 66.7% of samples grading from + to ++, with the 
remainder grading -/+  (Appendix I). FDA C is a discontinued urabe based vaccine called Pariorix 
which has been proven to exhibit CNS complications. The FDA D sample is related to the FDA C 
sample, it is isolated from a patient with Pariorix vaccine-associated meningitis, which could be
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the reason these two samples are closely related in terms of percentage lateral ventricle size 
(5.71% for the former and 5.2% for the latter). The Students un-paired T-Test gives a P value
of 0.972 for these two samples, suggesting a low probability of these two samples are related
as a random event.
The FDA E sample exhibits a 2.58% scoring for lateral ventricle size. This is a Jeryl Lynn based 
vaccine and would therefore have expected the scoring to be much lower, based on 
observations made throughout this study. However, this vaccine has been passaged three times 
in vero cells, which as this study has concluded, may cause the virus to increase in 
neurovirulent potential. The NIBSC scoring for this sample was 85% negative with 15% grading 
+ to ++  (Appendix I).
The FDA A sample has the smallest scoring for lateral ventricle size of all the FDA samples, 
which is concurrent with it being a JL vaccine from Merck and Co (1.3%). However, compared 
to the MSD JL vaccine that was used by NIBSC in this study, this is relatively high, 0.14% 
compared to 1.3%. This could be due to the composition of the JL P3 vaccine, it is unknown 
whether it is only one of the isolates, JL2 or JL5, or a mixture of the two as MSD JL is. The 
NIBSC scoring showed 94.7% of samples as negative with the remainder grading + to ++.
The samples were organised to range from most neurovirulent activity to the least (Table 5.1), 
the uncovering of these samples concurs with that list. Thus these blinded samples have lent 
weight to strengthen the belief that the rat model acts as a reliable indicator of the 
neurovirulent activity of a mumps virus based vaccine or sample.
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Appendix II.
FDA Scoring of NIBSC samples
Table 1 : Lateral Ventricle size of animals inoculated with the Lol/Mu90 Positive Control 
Virus
Animal Designation Area of Brain covered by Lateral Ventricle 
%
1 4.5
2 6.3
3 6.3
4 16.1
7 19.9
68 22.9
69 15.7
70 19.6
71 15
77 14.6
127 2.3
130 7.4
131 11
132 6.7
134 12
135 11.9
137 10.7
192 10.6
194 20.1
245 21.9
247 4.8
249 10
250 0.6
252 20.4
296 10.4
330 21.8
336 13.3
340 11.8
378 0.5
Mean Value : 12.04
186
Table 2: Lateral Ventricle size of animal inoculated with the SKB JL Bulk Vaccine
Animal Designation Area of Brain Covered By Lateral Ventricle 
%
11 7.2
13 3.6
15 1.7
16 3.6
17 0
79 0
85 0
140 0
142 3.6
144 0
257 4.9
299 1.1
305 1.8
307 1.8
344 4.4
346 1.4
351 16.3
387 0
388 0
391 3.7
Mean Value : 0.24%
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Table 3: Lateral Ventricle size of animals inoculated with SKB Urabe Bulk Vaccine.
Animal Designation Area of Brain Covered by Lateral Ventricle 
%
262 3.5
263 7.3
264 1.7
265 -
266 0
267 2.6
268 -
269 3.1
270 1.1
271 1.5
272 5.5
273 2.1
274 1.8
275 2.8
276 3.7
277 0.5
278 -
279 2.8
280 -
Mean Value 2.7%
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Table 4: Lateral Ventricle Size of animals inoculated with Lo4 Urabe isolate.
Animal Designation Area of Brain Covered By Lateral Ventricle 
%
148 1.1
149 3.4
150 0.25
151 0
152 -
153 1.45
154 1.95
155 -
156 1.65
157 6
158 1.55
159 3.4
160 1.55
161 -
162 2.8
163 0
164 2.65
165 2
166 1.7
167 -
Mean Value : L.96% (2%)
189
Table 5: Lateral ventricle Size of Animals inoculated with Nt5 Urabe virus.
Animal Designation Area of Brain Covered by the Lateral 
Ventricle %
22 0
23 5.25
24 16.8
25 1.75
26 0.65
27 5.1
28 3.6
29 2.65
30 5.9
31 3.45
32 0
33 6.05
34 12.65
35 4.95
36 3.25
37 0.7
38 3
39 3.95
Mean Value : 4.37%
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Table 6: Lateral Ventricle Size of animals inoculated with the JL MSD Bulk Vaccine.
Animal Designation Area of Brain Covered by the Lateral 
Ventricle %
88 0
89 0
90 0
91 0
92 0
93 0.5
94 0
95 0
96 0
97 0
98 0
99 0
100 0
101 0
102 2
103 0
104 0
105 0
Mean Value : 0.14%
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Table 7: Lateral Ventricle Size of animals inoculated with JL2 sub-component
Animal Designation Area of Brain Covered by Lateral Ventricle 
%
206 1.55
207 2.5
208 0
209 2.1
210 0
211 0
212 1.25
213 1.3
214 0.95
215 0
216 2.65
217 2.55
218 0
219 0
220 0
221 0
222 3.7
223 0
224 0
Mean Value : 1%
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Table 8 : Lateral Ventricle Size of animals inoculated with the JL5 sub-component
Animals Designation Area of Brain Covered by the Lateral 
Ventricle %
225 0.8
226 5.05
227 1.45
228 18
229 2.45
230 3.3
231 8.9
232 2.65
233 5.1
234 2.65
235 1.9
236 2.7
237 2.05
238 3.05
239 5.95
240 2.95
241 5.6
242 13.7
243 3
Mean Value : 4.8%
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Table 9: Lateral Ventricle size of animals inoculated with the diluent.
Animal Designation Area of Brain Covered by the Lateral
Ventricle %
393 3
394 0
395 0
396 -
397 0
398 0
399 1
400 0
401 0
402 0
403 -
404 0.4
405 0
406 0.2
407 0
408 0
409 -
410 0
411 0
Mean Value : 0.28%
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Table 10: Lateral Ventricle size of animals inoculated with the Clinical Material 99-0333
Animal Designation Area of Brain Covered by the Lateral 
Ventricle %
281 1.85
282 4.25
283 -
284 2.3
Mean Value : 2.8%
Table 11: Lateral Ventricle size of animals inoculated with the Clinical Material 99-0333V
Animal Designation Area of Brain Covered by the Lateral 
Ventricle %
285 1
286 3.56
287 -
288 5.9
Mean Value : 3.48%
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FDA Scoring of FDA Samples
Table 12: Lateral Ventricle size of animals inoculated with the FDA A Sample.
Animal Designation Area of Brain Covered by the Lateral 
Ventricle %
168 2.3
169 0.25
170 0
171 -
172 1.3
173 0
174 1.6
175 2.15
176 0.5
177 1.4
178 0
179 1.75
180 7.3
181 1.3
182 0.5
183 1.25
184 1.1
185 0.85
186 0
Mean Value : 1.3%
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Table 13: Lateral Ventricle size of animal inoculated with the FDA B Sample
Animal Designation Area of Brain Covered by the Lateral 
Ventricle %
352 38
353 24.5
354 4.2
355 32
356 -
357 25.5
358 19
359 28
360 14.5
361 18
362 41
363 16.5
364 22
365 9.1
366 -
367 14.5
368 24.5
369 36
370 29
371 32
372 -
373 25.5
374 28
Mean Value : 24.04%
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Table 14: Lateral Ventricle size of animals inoculated with the FDA C Sample
Animal Designation Area of Brain Covered by the Lateral 
Ventricle %
40 11.9
41 4.2
42 5.9
43 14.7
44 1.7
45 3.5
46 1.6
47 2.2
48 6.4
49 7.8
50 4.4
51 3.4
52 5.8
53 2.2
54 5.2
55 10
56 3.5
57 -
58 2
59 5.3
60 12.5
61 -
Mean Value : 5.71%
198
Table 15: Lateral Ventricle size of the animals inoculated with the FDA D Sample
Animal Designation Area of Brain Covered by the Lateral 
Ventricle %
106 15.5
107 0
108 2.5
109 0
110 8.9
111 0
112 0.4
113 20.6
114 0.25
115 0.6
116 5.5
117 10.9
118 4.4
119 8.9
120 10.3
121 8
122 6.3
123 1
124 11.3
125 0
Mean Value : 5.2%
199
Table 16: Lateral Ventricle size of the animals inoculated with FDA E Sample
Animal Designation Area of Brain Covered by the Lateral
Ventricle %
310 2.6
311 1
312 0
313 10
314 0
315 0
316 0.7
317 0.4
318 16.9
319 5.6
320 5
321 1.8
322 0.4
323 0
324 0
325 3.1
326 0
327 0.8
328 0
329 3.3
Mean Value : 2.58%
2 0 0
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